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Abstract 
The innate immune system has evolved a complex and highly regulated system to sense 
foreign pathogens and injury through the recognition of associated molecules by special 
receptors, the so called pattern recognition receptors (PRR). One group of intracellular 
PRRs is the family of Nod-like receptors (NLRs) that can sense various pathogens as 
well as danger associated molecules and trigger the release of pro-inflammatory 
cytokines and/or the transcription thereof. Genetic variations in key proteins can alter 
signaling events and may lead to innate immune disorders. A prototype of such a disorder 
is the Familial Mediterranean Fever (FMF), where patients develop spontaneous attacks 
of inflammation without pathogenic infections. FMF is caused by genetic alterations of 
the gene encoding the protein pyrin/TRIM20.  
Pyrin belongs to the tripartite motif-containing family of proteins that is characterized by 
a shared domain architecture comprising a RING finger, a B-Box and a predicted coiled 
coil domain. Pyrin has no functional RING domain, but possesses an N-terminal pyrin 
domain and, as most other TRIMs too, a C-terminal B30.2 domain. The function of pyrin 
seems to be two-fold. It can act in a pro-inflammatory manner similar to the NLRs, but it 
can also inhibit the NLR mediated release of pro-inflammatory cytokines. Structurally, 
only single domains of homologous proteins were solved, but none of pyrin. There is also 
a lack of information on how these domains are structurally arranged in the full length 
protein. In this thesis i) structural information on pyrin or fragments of it, ii) the effect of 
FMF associated mutations, and iii) biochemical analysis of interactions of pyrin with 
ligands was quested. 
Structure determination by X-ray crystallography of the pyrin B30.2 domain and several 
FMF associated mutants thereof identified that the domain folds identical to other B30.2 
domains and that mutations alter the binding epitope commonly found in these domains. 
Mutations in the central cavity of the epitope, including M694V that confers a severe FMF 
phenotype, lead to changes in the shape of the cavity. Mutations in loop regions alter 
their conformational flexibility and led to the identification of an important stabilizing 
hydrogen bond network between two loops. Our results provide detailed insights into the 
characteristics of both the shape and loop flexibility of the binding epitope that are altered 
in FMF mutants. 
The B30.2 domain in isolation is a monomer. The crystal structure of the B30.2 domain 
connected through a linker to the predicted coiled coil domain shows for the first time 
how TRIM proteins dimerize. The coiled coil and the proposed linker region form a central 
helical scaffold (CHS) domain. The monomeric CHS is composed of a 155 Å long helix, 
a turn of two short helices followed by an elongated stretch and a forth helix antiparallel 
to the long helix. The CHS domain dimerizes in an antiparallel fashion along the first helix 
positioning the flexibly attached B30.2 domains close to the dimeric 2-fold axis and the 
N-termini of the two monomers 167 Å apart. Based on the structure, a stereotype full 
length TRIM was modeled illustrating the arrangement of the domains. In addition, a 
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crystal contact between two neighboring dimers suggests a new mechanism on how 
TRIM proteins may form tetrameric structures. The ability to form higher oligomers 
beyond dimerization has been shown for several TRIM proteins, but the contribution of 
each domain was not fully understood. Our structure provides a model for the initial step 
of the higher oligomer formation through the presented dimer dimer contact. The contact 
also involves FMF associated residues as well as loops of which the flexibility is altered 
by FMF mutations. 
The dimeric construct also allowed us to investigate the suggested binding of pyrin to 
proInterleukin-1β (pro-IL-1β). Co-immunoprecipitation and Surface Plasmon Resonance 
experiments showed a clear interaction and revealed that pyrin is present in two states 
that bind to pro-IL-1β with different affinities. Size exclusion experiments reveal the 
formation of a high molecular weight complex. These results suggest that pyrin binds 
pro-IL-1β tightly when present as a higher oligomer most likely as a tetramer. As this 
interaction is linked to the inhibition of Il-1β maturation, the oligomerisation state of pyrin 
may play a regulatory role in the modulation of Il-1β.  
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Zusammenfassung 
Pathogene und Verletzungen werden durch ihnen assoziierte Moleküle (sog. PAMPS 
und DAMPS) von speziellen Rezeptoren des angeborenen Immunsystems erkannt. Eine 
Familie dieser Rezeptoren bilden die NOD-ähnlichen Rezeptoren (NLR). Die Erkennung 
von PAMPS und DAMPS aktiviert die Expression entzündungsaktivierender Proteine und 
die Maturation von Zykokinen. Eine genetische Veränderung involvierter Proteine kann 
zu Veränderungen in der Signalweitergabe führen, welches in einigen Fällen 
Autoentzündungskrankheiten auslöst. Ein Beispiel dieser Krankheiten ist das gemeine 
Mittelmeerfieber (FMF), welches durch genetisch bedingte Veränderungen des Proteins 
Pyrin/TRIM20 hervorgerufen wird und sich durch spontane Fieberattacken kennzeichnet. 
Pyrin gehört zur Gruppe der ‚tripartite motif containing‘ (TRIM) Proteine. TRIMs besitzen 
eine konservierte Domänenarchitektur, die aus einer RING Domäne, einer B-Box 
Domäne und einem ‚coiled coil‘ (CC) Motiv bestehen. Pyrin besitzt keine funktionelle 
RING Domäne, jedoch eine N-terminal Pyrin Domäne (PYD), und wie die meisten TRIMs 
eine zusätzlich C-terminale B30.2 Domäne. Die Funktion von Pyrin ist einerseits die 
Inhibierung einer NLR ausgelösten Immunantwort, es kann jedoch auch eine solche 
Antwort selbst induzieren. Strukturell ist Pyrin gänzlich unerforscht, lediglich Strukturen 
einzelner Domänen homologer Proteine sind bekannt 
Das Ziel dieser Arbeit war es i) Pyrin oder Fragmente von Pyrin strukturell aufzuklären, 
ii) den Effekt von FMF assoziierten Mutationen zu analysieren und iii) Bindungen von 
Pyrin zu Liganden in-vitro biochemisch zu untersuchen.  
Die Strukturbestimmung der C-terminalen B30.2 Domäne und mehrerer ihrer FMF-
assoziierten Mutanten zeigt einerseits die domänentypische Faltung. Andererseits 
zeigen die Mutanten Veränderungen im allgemein angenommenen Bindungsepitop. 
Mutationen in der zentralen Bindungstasche des Epitops verändern hauptsächlich 
dessen Form, wohingegen Mutation in flexiblen ‚Loops‘, deren konformative Flexibilität 
beeinträchtigen. Die gelösten Strukturen ergeben ein detailliertes Bild der B30.2 Domäne 
und der Eigenschaften ihres Bindungsepitops. 
Die isolierte B30.2 Domäne ist monomer in Lösung. Die Struktur des C-terminalen 
Fragmentes von Pyrin bestehend aus dem CC Motiv, einem Linker und der B30.2 
Domäne zeigt zum ersten Mal die antiparallele Dimerisierung der TRIM Proteine. Das 
CC Motiv und der Linker bilden dabei eine zentrale helikale Gerüstdomäne (CHS), an 
welcher die B30.2 Domäne flexibel nahe der zentralen 2-fach Achse angebracht ist. Die 
N-termini beider Peptidketten liegen jedoch 167 Å voneinander entfernt. Damit kann zum 
ersten Mal gezeigt werden, wie die genaue Domänenarchitektur in TRIM Proteinen 
aussieht. Des Weiteren kann aus der Kristallstruktur ein Tetramer postuliert werden, 
welches als Baustein einer multimeren Selbstassemblierung dienen kann. Eine solche 
Selbstassemblierung wurde für mehrere TRIM Protein gezeigt. 
Das dimere Konstrukt erlaubte uns ebenfalls, die postulierte Bindung von Pyrin zum 
Zytokine proInterleukin-1β (pro-IL-1β) zu messen. Co-Immunoprezipitations-  und 
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Oberflächenplasmonenresonanzexperimente beweisen die Interaktion beider Proteine 
in-vitro, wobei Pyrin in zwei verschiedenen Zuständen vorkommt, welche pro-IL-1β mit 
unterschiedlicher Affinität binden. Ein Komplex beider Proteine konnte mittels Gel-
Permeations-Chromatographie detektiert werden, und zeigt ein hohes scheinbares 
Molekulargewicht des Komplexes. Die Resultate suggerieren, dass Pyrin pro-IL-1β mit 
höherer Affinität bindet, sofern es als höheres Oligomer (Tetramer) vorliegt. Da die 
Bindung von Pyrin zu pro-IL-1β dessen Maturation inhibieren soll, könnte der oligomere 
Zustand von Pyrin eine regulatorische Funktion besitzen. 
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1 Introduction 
1.1 Innate Immune System 
The innate immnue system is the first line of defense against foreign pathogens 
and tissue damage. The ability to sense pathogens as well as injury and the 
capability of clearance by phagocytosis, the innate immune system provides a fast 
and general defense mechanisms against harmful factors. The recognition of 
tissue damage and foreign invaders, such as bacteria, viruses, and fungi is 
performed by the soluble factors of the complement system and specialized white 
blood cells, namely monocytes, neutrophils, macrophages or dendritic cells. Upon 
recognition a local and systemic response is induced by releasing signaling 
molecules (e.g. chemokines and cytokines). The systemic response leads to the 
production and differentiation of white blood cells in the bone marrow, the secretion 
of acute phase response reactants by the liver, the onset of fever and the activation 
of the adaptive immune system. The local response includes an increased blood 
flow and vasodilatation at the site of action that allows the recruitment of a larger 
set of phagocytic cells, activation of phagocytosis, and the secretion of 
antimicrobial substances1,2. The sensing of pathogens and cell damage by white 
blood cells is mediated through a germ-line encoded set of proteins, which 
recognize special molecular patterns associated to pathogens and broken cells, 
called pathogen and danger associated molecular patterns (PAMPS, DAMPS). 
This set of proteins includes cell surface receptors and cytoplasmic receptors that 
comprise four families of proteins: the membrane bound toll-like receptors (TLR) 
and C-type lectin receptors (CLR) and the intracellular nucleotide-binding and 
oligomerization domain (NOD)-like receptors (NLR), and the retinoic acid-inducible 
gene I (RIG-I)-like receptors (RLR). They all have sensing domains for specific 
PAMPS or DAMPS. Upon binding of PAMPS or DAMPS, the receptors oligomerize 
and induce either a signaling cascade that leads to the transcription of several 
inflammatory proteins or/and induce the secretion of cytokines to the extracellular 
space. 
1.2 Pattern Recognition Receptors 
An overview of the known PRR is shown in figure 1.  
1.2.1  TLRs 
TLRs are the best characterized set of PRRs. They are type-1 membrane proteins 
and comprise an extracellular leucine-rich-repeat (LRR), a transmembrane domain 
and an intracellular toll/Interleukin-1 receptor homology (TIR) domain that triggers 
signal transduction. There are eleven human members known of this family. TLRs 
can sense a variety of PAMPS, such as viral RNA and DNA, bacterial cell wall 
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components like lipopolysaccharide (LPS) and bacterial flagellin. The extracellular 
LRRs have a varying number of repeats, ranging from 18 to 25, where each repeat 
is between 22-29 amino acids in length and has a distinct interval of leucines3. 
They form a horseshoe like structure and act as the PAMP sensing domain through 
their ability to directly bind to PAMPS in a versatile way4-6. The sensing of PAMPS 
leads to the activation of TLRs that induces a signaling cascade in the cytoplasm. 
This cascade is characterized by protein-protein interactions and protein 
modifications such as ubiquitination and phosphorylation that alter the functions of 
the participating proteins. As most proteins involved are present in an inactive state 
the modifications are needed for further signal transduction7. For several TLRs the 
following cascade has been described following TLR activation that is initiated at 
the intracellular TIR domain. Via the TIR domain the Myeloid differentiation primary 
response protein 88 (MyD88) is recruited. Myd88, sometimes in association with 
the TIR domain containing adaptor protein (TIRAP) then recruits the interleukin-1 
receptor-associated kinase 1, 2 and 4 (IRAK1,2, and 4) and the tumor-necrosis-
factor (TNF)-receptor associated factor6 (TRAF6). TRAF6 promotes the formation 
of K63-linked polyubiquitin chains linked to IRAK1 and TRAF6. These ubiqutin 
chains allow the binding and induction of two kinase complexes, namely the IκB-
kinase complex (IKK) and the transforming growth factor β-activated kinase 1 
(TAK1) in complex with the TAK1-binding protein 2 and 3 (TAB2, 3)8. Both these 
complexes activate the mitogen-activated protein kinase (MAPK) cascade that 
eventually leads to the activation of transcription factors, such as the nuclear factor 
κB (Nf-κB) and the activating protein 1 (AP-1)9. These transcription factors induce 
the expression a large set of inflammatory cytokine, chemokines and inflammatory 
associated proteins and in this way induce an innate immune response upon the 
recognition of PAMPS.  
1.2.2  CLRs 
The other group of membrane bound PRRs are the CLRs. They are mostly 
involved in sensing components of the fungal outer membrane, in particular 
carbohydrates like β-glucan and mannan10. The signaling occurs differently than 
seen for TLR. Through their cytoplasmic immunoreceptor tyrosine-based activation 
motif (ITAM) they recruit and activate the protein kinase C (PKC)δ which leads to 
the formation of a caspase-recruitment domain protein 9 (CARD9) dependent 
complex followed by the activation of Nf-κB and AP-1 transcription factors. 
NLR and RLR are the intracellular receptors. RLRs are involved in the recognition 
of cytoplasmic viral RNA. The NLRs are activated upon a large set of PAMPS and 
DAMPS.  
1.2.3  RLRs 
RIG-I as a member of the RLR senses 5’-phophorylated and double stranded (ds) 
RNA of viral origin in the cytoplasm. RIG-I consist of the N-terminal tandem CARD 
motif, followed by a DExD-box RNA helicase domain and a C-terminal domain 
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(CDT) that binds to the RNA. Once the RNA is sensed, the CARD tandem motif is 
released from its autoinhibitory conformation and is able to recruit the tripartite-
motif containg protein 25 (TRIM25). TRIM25 induces the formation of unanchored 
K63-linked polyubiquitin chains that allows the binding of RIG-I to the mitochondrial 
antiviral signaling protein (MAVS) that induces further downstream signaling and 
transcriptional activation11,12. 
1.2.4  NLRs 
The NLRs have a central NOD domain and a C-terminal LRR. The N-terminal 
domain is variable and may contain a CARD, Pyrin domain (PYD), a Baculovirus 
inhibitor of apoptosis protein repeat (BIR) domain or other domain. Depending on 
their N-terminal domain they are called NLRP (NOD, LRR and PYD domain contain 
proteins) , NLRC (NOD, LRR and CARD domain containing proteins) or NAIP (BIR-
containing protein). In humans NLRP1-12, NLRC1-5 and NAIP are found. Not all 
members of these groups are functioning as a PRR, as this functions has only 
clearly been assigned to NLRP1, 3, 6 and 12, NLRC1, 2 (also called NOD1 and 2) 
and NLCR 4 and NAIP. Whereas NOD 1 and 2 are involved in Nf-κB activation 
upon recognition of peptidoglycans via the recruitment of the receptor-interacting 
protein kinase 2 (RIP2), NLRP1,3,6,and 12, NLRC4 and NAIP are involved in the 
activation and release of the proinflammatory cytokines proInterleukin-1β (pro-IL-
1β) and prointerleukin-18 (proIl-18) via platforms that are termed inflammasome13. 
 
Figure 1: Overview of Pattern Recognition Receptors and their downstream signalling events.  
Taken from Ishii et al., 200814. The proteins are named as indicated in the text. 
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1.3 The inflammasome 
Inflammasomes are mulitprotein complexes that lead to the maturation of 
proInterleukin-1β (pro-IL-1β) and proInterleukin-18 (proIl-18). Both cytokines are 
expressed as inactive proforms and need to be proteolytically processed to the 
mature form. The enzyme responsible for the proteolytic activation is the Cystein-
dependent aspartate-directed protease 1 (caspase-1). Caspase-1 is one of 12 
caspases found in humans that are expressed as zymogens. Caspases are 
cysteine proteases that cleave C-terminal of an aspartic acid and are involved in 
cytokine processing but also in of apoptosis, also called programmed cell death. 
They are therefore grouped into inflammatory and apoptotic caspases. The 
inflammatory caspases include caspase-1, -4, -5 and -12. Caspases share the 
same domain architecture in their catalytic domain, having a small and large 
subunit. Inflammatory, as well as some apoptotic members have an additional 
recruitment domain that in case of Caspase-1 is a CARD domain. The CARD as 
well as the earlier mentioned PYD domain belongs to the group of death domains 
(DD) that are shown to interact in a homotypic manner with other DD-containing 
proteins15. The formation of the inflammasome greatly relies on such homotypic 
interactions. 
A first step in inflammasome activation is the sensing of a stimulus. The direct 
stimuli is in most cases not known and has only been clearly proven in case of 
NLRP1, murine NAIP5 and NRLX1 (containing an N-terminal X-1 domain), which 
have been shown to directly interact with muramyl dipeptide, bacterial flagellin and 
RNA, respectively. The best characterized inflammasome, formed by NLRP3, is 
activated by a large variety of signals that change the cytoplasmic environment 
upon cellular stress and damage. Activation can occur by such different stimuli 
such as extracellular ATP, nigericin, changes in the osmotic pressure by pore 
forming toxins, or reactive oxygen species13. It is also associated with viral 
infections. In all cases the stimulation induces the oligomerization of the NLRs into 
large disc-like structures and the recruitment of other proteins to the 
inflammasome16,17. Recently, the crystal structure of the NLRC4 has been solved 
in its auto-inhibited state. The structure reveals that the LRR region binds to the 
NOD domain and through this intramolecular binding inhibits the oligomerisation of 
NLCR4, illustrating the need for stimulus binding to multimerize18. Through their N-
terminal domain, NLRC4 for example can directly recruit procaspase1 via 
homotypic CARD-CARD interaction19. In case of NLRP3, this requires the adaptor 
protein Apoptosis-associated Speck-like protein containing a CARD (ASC), which 
possesses both a CARD and a PYD and therefore acts as a bridging or adaptor 
molecule to recruit procaspase-120. The recruited zymogen procaspase-1 then 
autoactivates itself through an induced proximity mechanism that leads to the 
proteolytic cleavage of the polypeptide chain of procaspase-1 at three distinct sites. 
Procaspase-1 is cleaved C-terminal of the recruitment domain at residue 119 and 
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between the small and big subunits at residues 297 and 31621. The resulting p10 
and p20 subunit form a heterotetrameric active caspase-1, and in this respect the 
inflammasome is regarded a caspase-1 activation platform. Caspase-1 modifies 
its substrates proteolytically as it is the case in the cleavage of proI-1β that occurs 
at two sites. The first cleavage occurs within the prodomain at aspartate 28. The 
second cleavage occurs at aspartate 116, yielding the active C-terminal 
fragment22,23. 
1.4 Interleukin-1β 
The result of inflammasome formation is the maturation of Il-1β, which is a potent 
pro-inflammatory cytokine that upon its maturation is released into the extracellular 
space by non classical secretion pathways24. Il-1β acts in a paracrine and autocrine 
manner to amplify the inflammatory response of the innate immune system. It binds 
to Il-1 receptors (Il-1R) that in a similar manner as described for the TLRs lead to 
the activation of Nf-κB through a cascade initiated by the cytoplasmic TIR domain. 
Via this signaling cascade Il-1β induces the transcription of a large set of genes in 
various cell types that mediate a systemic pro-inflammatory response25. Due to the 
systemic and potent effect if this cytokine, Il-1β is regulated at various stages 
ranging from the gene transcription, mRNA lifetime, expression as precursor, 
maturation, secretion, and receptor binding26. It is therefore not surprising, that 
alterations in the regulation of Il-1β activity are associated to diseases. One 
example are alterations of the gene coding for NLRP3, which cause cryopyrin (an 
older name for NLRP3) associated periodic syndromes (CAPS), which belong to 
the group of auto-inflammatory diseases. Mutations in the gene are thought to 
either cause increased expression of NLRP3 or alter the auto-inhibited state of 
NLRP327. Due to their association to increased pro-IL-1β maturation, treatment 
usually occurs with Il-1R antagonist or anti-Il-1β monoclonal antibodies. Another 
prototype of an auto-inflammatory disease is the Familial Mediterranean Fever. 
1.5 Familial Mediterranean Fever 
Familial Mediterranean Fever (FMF; OMIM #249100) is an autosomal recessive 
disorder and represents a prototype of hereditary recurrent fevers or 
autoinflammatory diseases that are characterized by recurrent episodes of fever 
without any signs of pathogenic infection25,26. In contrast to auto-immune diseases 
there is no increased titer of auto-reactive T-cells28. FMF is mostly found within 
ethnics of the eastern Mediterranean basin, such as Arabs, Armenians, Turks, and 
non-Ashkenazi Jews. Within these populations the carrier frequency for 
heterozygotes varies. In Turks and non-Ashkenazi Jews frequency was reported 
to be 1:13 and 1:11,4, respectively29.  The highest carrier frequency is observed in 
Armenians being as high as 1:3. The disease onset is usually found within the first 
20 years of live30.  
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In FMF patients, the recurrent episodes of fever are accompanied by peritonitis, 
acute synovitis of joints and pleuritis mediated by an increased migration of 
neutrophils into these tissues. The self-limiting inflammatory attacks usually last for 
a few days up to one week with intervals of weeks up to month, where patients are 
symptom free31. An inflammation mediated chronic secretion of the acute phase 
reactant serum amyloid A (SAA), can lead to amyloidosis, which represents the 
most severe pathological consequence. The deposition of amyloid A fibrils in the 
kidney can lead to a nephrotic syndrome and renal failure32. The sudden onset of 
inflammatory attacks is triggered by environmental factors such as exposure to 
cold, psychological stress, tiredness and menstruation33.  
FMF is diagnosed by the evaluation of apparent symptons according to the Tel-
Hashomer criteria34. The disease is treated with colchicine at a dosis of 1-2 mg 
daily or in case of colchicine resistance with anakinra, an Il-1R antagonist35,36. 
Colchicine is an inhibitor of microtubule association, able to reduce neutrophil 
migration. It is effective in abolishing the symptons as well as preventing 
amyloidosis. In 1997, two consortia independently identified the gene responsible 
for FMF, the Mediterranean Fever gene37,38. This gene codes for protein that was 
called pyrin, to recall its association to fever. Pyrin belongs to the family of tripartite-
motif containing proteins. 
1.6 TRIM proteins 
Tripartite motif-containing proteins comprise a large family of proteins that share a 
common domain architecture. This motif consists of a Really-Interesting-New-
Gene (RING) finger domain, one or two B-Box domains and a predicted coiled coil 
domain. The motif is also referred to as RBCC39,40. Members of this family are 
found in all metazoan41,42.  The size of the protein family varies greatly across 
different species. According to Ozato et al, there are 65 human members, 64 in 
mice, 20 in worms and less than 10 in flies42. The fact that the tri-partite motif can 
be flanked by different domains and the low sequence similarity found in some 
parts makes an exact determination of the family size difficult.  
The TRIM family can be divided into twelve subfamilies that are grouped according 
to the domains found in addition to the RBCC motif (see Fig. 2)43. Subfamilies I to 
XI all possess a RING domain, whereas the twelfth group contains members where 
no RING domain is present. Despite some members having no RING domain, 
there are other members that have no apparent B-Box or predicted coiled coil. 
However, if single domains are missing, the remaining domains are conserved in 
order and spacing42.  
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Figure 2. The tripartite motif and domain composition of the different TRIM subfamilies. The subgroup C-XII 
is not depicted. The abbreviations for the domains are as described in the text. Adapted from Short et al., 
200644. 
 
1.6.1  The TRIM motif 
Although TRIM proteins are involved in various different cellular processes, distinct 
functions can be assigned for each of the domains found in the common tripartite 
motif. 
1.6.2  RING finger 
RING domains are between 40 and 60 residues in length and share a common 
motif of eight conserved residues able to coordinate divalent cations such as 
zinc45,46. First structures of RING domains revealed the mode of coordination of 
two zinc atoms47,48. The ββα fold of the RING domain coordinates the first zinc 
atom via the first and second conserved cysteine together with cysteine five and 
six in a tetrahedral manner (CCCC finger). The second zinc-finger is made by a 
cysteine and a histidine at position three and four and the last two cysteines (CHCC 
finger; see Figure 3A and 4). This cross brace manner of zinc coordination is a 
characteristic feature of RING domains, and was later also shown in related 
domains, such as the B-Box domain (see below).  First insights into the function 
were revealed by several groups showing that the Ring Box protein 1 (Rbx1) is 
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involved in the ubiquitination of Sic1, an inhibitor of cell cycle progression. The 
ability to act as an E3 ligase was then found for several unrelated RING containing 
proteins, suggesting the E3-ligase activity as a common function of RING domain 
containing proteins49. Through genome wide screening more than 300 proteins 
containing a RING domain are now identified in the human genome50. The largest 
protein family found within these RING containing proteins is the TRIM family with 
approximately 78 members. Soon after the discovery of the E3-ligase activity of 
RING domains, first evidence was presented that also TRIM proteins are involved 
in ubiquinitation process of target proteins in a RING dependent manner. 
TRIM18/MID1 for example, was shown ubiquitinylate PP2A, the microtubule 
associated phosphatase 2A51,52. TRIM25 was shown to target 14-3-3σ, a negative 
cell cycle regulator that causes G2 arrest, to proteosomal degradation by 
ubiqitination53. Besides targeting proteins for degradation through so called K48-
linked ubiquitination, several TRIM proteins were also shown to activated an innate 
immune response by creating unanchored K63-linked poly-ubiquitin (poly-ub) 
chains54,55. The type of ubiquitination is dependent on the E2-conjugating enzyme. 
TRIM proteins have been shown to able to recruit both types of E2-enzymes that 
either tag target proteins with K48-linked poly-ub chains or are capable of 
producing unanchored K63-linked poly-ub chains. The type of ubiquitination has 
clearly been demonstrated for a few TRIM proteins. TRIM5α and TRIM21 have 
been shown to induce K63 unanchored poly-ub formation, whereas TRIM27 links 
K48-linked poly-ub chains to target proteins56-58.  
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Figure 3: The tripartite motif: A) Structures of the Zinc-fingers are shown in a cartoon representation. The 
residues involved in the cross brace coordination of the Zn2+ (red spheres) are shown as sticks. B) Two 
interactions are proposed for the B-Box2. The formation of dimers was seen for TRIM63, and a B-Box1 B-
Box2 interaction was seen in the solution structure of TRIM18. The central B-Box2 is in the same orientation 
and color as in A. The second B-Box2 found in the dimer is shown on the left and colored in orange. B-Box1 
is colored as in A. 
1.6.3  The B-Box 
In TRIM proteins, two type of B-Boxes are found that differ in their zinc binding 
consensus motif and overall length, B-Box type 1 (B-Box1) and B-Box type 2 
(B-Box2). With some few exceptions B-Box domains are exclusively found in TRIM 
proteins. The B-Box1 is only found in a few members of the family, the B-Box2 
though is present in all TRIM proteins and is regarded the determinant of the TRIM 
family of proteins59. Solution structures of B-Box1 and B-Box2 revealed their 
similarity to the RING domain as they also fold into ββα structures60,61. In case of 
the B-Box2 this motif is followed by an additional third β-strand (see Fig. 3A). The 
coordination of the two zinc atoms occurs as seen in RING domains in a cross 
brace manner. The difference to the RING domain is that B-Box domains are 
shorter in length and have a changed consensus motif. The B-Box domains 
function as a protein a binding domain. In the crystal structure of TRIM63/MuRF1 
and TRIM54/MuRF3, the B-Box2 is present as a dimer59. The dimerization 
interface is formed by the α-helix of one protomer that binds into the concave side 
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of the β-sheet of the second protomer (see Figure 3B). In some TRIM proteins, the 
B-Box2 was found to be responsible for the formation of higher oligomers, probably 
due to the described ability to form homodimers. A prominent example is TRIM5α, 
where mutations of residues that correspond to residues within the dimerization 
interface found in TRIM63, led to the loss of function through the inability to form 
multimeric self-assemblies62. TRIM5α is a retroviral restriction factor that is 
dependent on the formation large self-assemblies, in order to potently restrict 
retroviruses. 
An interesting feature has been observed in the solution structure of the 
TRIM18/MID1 B-Box1 B-Box2 tandem motif63. The structure revealed that the two 
types of B-Box domains form a stable interaction. This interface is formed by 
residues of the structured loop between β1 and β2 of both B-Box domains, and is 
located on the opposite site of the B-Box2 homodimer interface (see Fig. 3B). 
Besides the contribution of the B-Box domain to form homotypic interactions, they 
have also been found to mediate other protein protein interactions. In case of 
TRIM18/MID1 the B-Box1 binds to the α4-subunit of the PP2A, targeting the later 
for degradation, as described above51.  
Just very recently, another function has been assigned for B-Box domains. In case 
of TRIM16, which harbors a B-Box1 B-Box2 tandem motif, but no RING domain, 
an E3-ligase activity has been assigned. However, it could not be clarified which 
of the B-Boxes confers this activity64. 
1.6.4  The Coiled Coil 
The coiled coil is an α-helical assembly of 2 or more parallel or antiparallel 
amphipathic helices. Their characteristic sequence motif is a heptad repeat pattern 
(abcdefg), where residues at position a and d are hydrophobic. As the α-helix has 
3.6 residues per turn, residues at these positions face the same side of the helix 
and make hydrophobic interactions with the corresponding residues of the partner 
helix/helices. The hydrophobic side chains pack into a  knob-into-hole manner, 
which means that the side chain of the amino acid at position a (knob) binds into a 
hole formed by residues d, g, a+1, and d+1 of the opposing helix65. The 
hydrophobic interactions are complemented by ionic interactions between charged 
residues at position e and g66 (see Figure 4). The remaining residues at position 
b,c and f are usually hydrophilic. The average distance for the hydrophobic 
residues in the CC sequence is 3.5, which is a little less then the 3.6 residues per 
turn observed in α-helices. This difference is the reason why the α-helices coil 
around each other forming a left handed superhelical assembly with 3.5 residues 
per turn with respect to the superhelical axis67. The type of hydrophobic residue 
found at position a and/or d can determine the degree of oligomerization68. 
Likewise observations have been made for the charged residues at position e 
and g69. The regular heptad repeat pattern can be disrupted by non-heptad 
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sequence motifs. These stutters (four residue insert) and stammers (three residue 
insert) decrease or increase the superhelical coil character of the CC, respectively. 
 
 
 
Figure 4: Indicated on the left are the residues of the heptad repeat pattern with their contributions to the 
coiled coil α-helical assembly. The knob into hole interaction as well as the ionic interactions are indicated on 
the right. Taken from Mason et al, 200469.   
 
The B-Box2 is in almost all TRIMs followed by a predicted coiled coil motif (CC)70. 
The length and probability of the predicted CC region differ for the different TRIM 
proteins. With three exceptions, the CC lies within the first 120 amino acids 
C-terminal of the B-Box2 and is bipartite, meaning there are stretches of two 
sequence regions that can be interpreted to form a CC.  
In a broad yeast-2-hybrid screening, most TRIMs studied were shown to form 
homo-oligomers in a coiled coil dependent fashion. In a few cases the formation of 
hetero-oligomers was found71. In case of TRIM5α and TRIM21, cross-linking 
experiments followed by SDS-PAGE analysis suggested the proteins to form 
trimers in a CC dependent manner72,73. However, it was later found that these 
putative trimeric species corresponded to dimers in solution when the oligomeric 
state was analyzed using purified proteins57,74,75. In case of TRIM5α, it was shown 
that the dimer formation does not only depend on the CC part, but also relies on 
residues C-terminal of the CC segment76. The ability of forming dimers has been 
shown to be essential for function as a deletion of either of the two CC regions 
leads to an inactive form of TRIM5α. Besides oligomerisation the CC region is also 
attributed to other functions. In both TRIM21 and TRIM27 cellular localization 
sequences were identified77,78.  
1.6.5  C-terminal domains 
As depicted in figure 2, a variety of additional domains can be fused at the C-
terminus of the tri-partite motif. These will be shortly discussed with a focus on the 
B30.2 domain which is found in more than half of TRIM proteins. In class C-I to C-
III a C-terminal subgroup one signature (COS) domain is found right C-terminal of 
the predicted CC. This approximately 60 residue long domain is predicted to form 
a 2 α-helical coiled coil and is associated with microtubule binding44. The 
Fibronectin type III domain (FN3) present in subgroup C-I and C-III is 
approximately 100 amino acids long and folds into an immunoglobuline-like fold 
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comprising of 7 β-strands forming two antiparallel β-sheets79. In non-TRIM proteins 
the FN3 domain are found in cell surface receptors, cytokine receptors or receptor 
protein tyrosine kinases. Their role in TRIM proteins is unknown. In subgroup C-II 
the COS domain is found together with an acidic rich (AR) sequence, which is 
thought to be intrinsically disordered and has not been assigned to a specific 
function, yet.  
In the subgroup C-VI a plant homeodomain (PHD) and a Bromo domain is found. 
The PHD finger belongs to the RING finger80. The Bromo domain forms a 4-helical 
bundle and recognizes acetylate lysines as found at the N-termini of histones81. 
The tandem motif of PHD domain and Bromo domain were shown to be important 
for TRIM28 to act as a transcriptional repressor82.  
The NHL (first identified in ncl-1 , HT2A , and lin-41) domain is found in subgroup 
C-VII83.  The structure of the NHL domain of the TRIM protein Brat from Drosophila 
melanogaster shows the domains six bladed β-propeller fold84. Brat acts as a 
translational repressor important in early development. 
The Meprin And TRAF-Homology (MATH) domain found in subfamily C-VIII is 
involved in protein-protein interactions85. The ADP ribosylation factor-like domain 
(ARF) is involved in protein trafficking, the filamine like Ig (FIL) domain is important 
in the process of actin crosslinking and transmembrane domain (TM) anchors the 
protein to the cellular membrane43. 
1.6.6  The B30.2 domain 
As mentioned the B30.2 domain is present of almost half of the TRIM proteins and 
is named after the exon it was first identified in86. In TRIM proteins it is either found 
in combination with COS-FN3 in subfamily C-I or as a single C-terminal domain in 
C-IV. Besides TRIM proteins, the B30.2 domain is also found in the Butyrophilin-
related protein family, which comprises membrane bound receptor glycoproteins 
and in the Stonustoxin, a cytolytic protein of the stonefish Synanceia horrida87 The 
B30.2 is closely related to a domain first identified in Dictyostelium discoideum 
dual-specificity kinase termed splA and in ryanodine receptors (RyR) domain that 
was named SPRY88. SPRY domains are found in a variety of proteins, e.g. the 
SPRY domain containing SOCX box (SSB) proteins that form multiprotein E3 
ubiquitin complexes and are involved in suppression of cytokine signaling89,90. 
Primary sequence analysis revealed the relationship between the B30.2 domain 
and the SPRY domain. Where the B30.2 domain is between 180-200 amino acids 
in length91, the SPRY domain is shorter in length. By identifying domain specific 
consensus motifs, it was shown that the SPRY domain motif is also found in the N-
terminal part of the B30.2 domain. However the B30.2 domain has an additional C-
terminal consensus motif not present in SPRY domains92. This extension is 
sometimes called PRY (for SPRY associated domain)91. Therefore the B30.2 
domain can also be called PRYSPRY as it contains a SPRY domain with a C-
terminal PRY extension. Structurally, the B30.2 folds into a six- and 
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seven-stranded β-sheet that form a β-sandwich. The sheets are connected by 
several loops in a jellyroll-like topology91. With respect to the subdomains PRY and 
SPRY, the PRY part consists of 3 β-strands and the SPRY domain of 10 β-strands. 
Both subunits are part of the globular structure of the B30.2 domain forming a 
single β-sandwich. Some of connecting loops between the strands are of variable 
length and show a high sequence variability between the different B30.2 domains 
(see Fig. 5). Structures of the SPRY domain show a very similar fold compared to 
the B30.2 domain. The SPRY part is also accompanied with a C-terminal extension 
that is an integrated component of the fold and structurally related to the PRY 
segment of the B30.2 domain89,93. 
The B30.2 and SPRY domains are thought to mediate protein-protein interactions. 
Several binding partners were identified for these domains. First structural insights 
into the mode of ligand binding were given by the dimeric PRYSPRY assembly of 
the similar to Ret-finger protein like 1 (sRFPL1), a protein of unknown function, the 
complex structure of TRIM21 binding to the Fc-region of an IgG, and the SPRY 
domain of GUSTAVUS binding to its interacting peptide89,94,95. The complex crystal 
structures revealed that in all cases a similar epitope is used to bind the ligand, 
which is created by the variable loops and the surface of the β-sheet (see Fig. 5). 
Besides the suggested common binding epitope, the mode of interaction between 
B30.2/SPRY domains is variable. In case of GUSTAVUS, the only SSB protein 
found in Drosophila melanogaster, its SPRY domain binds a linear peptide. 
TRIM21 binds to the Fc-region of the IgG via a complex interface binding to both 
the constant region 2 and 3 of the antibody’s heavy chain creating two non 
continuous binding areas on the B30.2 domain of TRIM21.  
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Figure 5: The B30.2 domains of TRIM21 and sRfpl1 with their bound ligands. The B30.2 domains are colored 
in red and green for their PRY and SPRY segment, respectively, and the bound ligand is colored in grey. The 
orientation of both B30.2 domains is identical. 
1.6.7  TRIM function 
TRIM proteins are involved in various processes and their different functions can 
mainly be attributed to the different C-terminal domains that lead to binding to 
different target proteins96. The tripartite motif then provides the platform for the 
effector function of the TRIM proteins. To illustrate the function of TRIM proteins, 
the binding to the target protein and the induced effect is illustrated for two well 
characterized TRIM proteins that belong to subfamily C-IV, namely TRIM5α and 
TRIM21. TRIM5α has been shown to potently restrict a variety of retroviruses and 
TRIM21 is an intracellular Fc-receptor.  
In humans, TRIM5α potently restricts the N-murine leukemia virus, whereas the 
rhesus macaque orthologue restricts the human immune deficiency virus 1 (HIV-1). 
Upon entry of the retroviruses into the host cell, TRIM5α recognizes the assembled 
capsid lattice. The recognition of the capsid is mediated by the C-terminal B30.2 
domain that directly interacts with the capsid proteins. Via interactions of the B-Box 
TRIM5α self-assembles into a multimeric lattice that engulfs the viral capsid cone97. 
Once self assembled, TRIM5α is able to induce the formation of K63-linked free 
ubiquitin chains through its RING domain. These K-63 linked ubiquitin chains 
induce the activation of the TAK-1 kinase complex which activates subsequently 
NF-κB and AP-1 induced transcription and expression of several inflammatory 
chemokines and cytokines57. In this manner TRIM5α acts as a PRR, as it senses 
directly the pathogen and induces downstream signaling. 
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TRIM21 acts as an intracellular Fc-receptor that also potently induces a pro-
inflammatory response. Pathogenic particles such as viruses and bacteria that 
circulate in the body are exposed to antibodies and may eventually be coated with 
antibodies capable of binding. Once in the cytoplasm, the antibodies can be 
recognized by TRIM21 through the described binding to the Fc-region by the B30.2 
domain. The binding of the TRIM21 to antibody coated pathogens induces again 
the formation of K63-linked free poly ubiquitin chains. This induces similar to 
TRIM5α the induction of the inflammatory cytokines. In addition TRIM21 
autoubiquitinates itself, therefore targeting the pathogen-antibody-TRIM21 
complex for proteosomal degradation, and therefore conferring clearance of the 
pathogen.  
1.7 Pyrin 
Pyrin is encoded by the Mediterranean fever gene (MEFV) located on the short 
arm of chromosome 1637,38. MEFV encodes the 781 amino acid long 
protein/TRIM20 that is a member of the TRIM protein family (see Figure 6 and 7). 
The N-terminal RING domain is degenerated as three out of eight conserved Zn2+ 
coordinating residues are mutated. It is therefore grouped to the subfamily C-XII 
which habors the RING-less members. However, with respect to the B-Box, CC 
and the C-terminal domain it belongs to the subfamily C-IV as it also harbors a 
B30.2 domain70. Additionally it has a long N-terminal insertion consisting of 303 
amino acids. At the N-terminus it harbors a 95 amino acid PYRIN domain (PYD). 
In the adjacent linker region it also contains a B-zip domain, that is thought to be 
responsible for translocation to the nucleus98,99. Pyrin is mostly localized in the 
cytoplasm, although a splice variant of pyrin, which is missing the linker region 
between the PYD and the degenerated RING domain, was found to localize in the 
nucleus100. Pyrin is mostly expressed in monocytes, macrophages, neutrophils and 
eosinophils and its expression is under control of a variety of cytokines including 
type I and type II interferons, Tumornecrosis factor α (TNF), but also of PAMPS 
such as LPS101,102. Pyrin was shown to form a trimer through the CC domain by 
crosslinking studies, however the limitations of this method were shown for TRIM5α 
and TRIM21 (see above) suggesting that pyrin is also present as a dimer.. 
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Figure 6: From gene to protein. A) The MEFV gene is located on the short arm of chromosome 16. B) The 
transcript consists of 10 exons, which are shown as grey boxes. Their length of the depicted box is in scale to 
their relative mRNA length. The introns are depicted as a black line and are not in scale. C) In the longest 
isoform, the MEFV gene encodes a 781 amino acid protein consisting of 4 domain (PYD: Pyrin domain). 
Adapted from Grandmange et al., 2008103. Mutations with a reported FMF phenotype are indicated as lines 
beneath the domain architecture of pyrin. 
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Figure 7: Sequence alignment of TRIM proteins of subclass C-IV: Conservation of residues is colored 
according to the BLOSUM62 score, where blue having the highest score. The domain boundaries are shown 
above the alignment in boxes. For the RING domain the cross-brace manner type of zinc coordination is 
indicated. Note that pyrin has lost 3 of the 8 conserved residues involved in zinc coordination. 
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PYRIN domain 
The PYRIN domain (PYD) belongs to the superfamily of death domains (DD). This 
superfamily is characterized by its globular fold comprising of 6 anti-parallel α-
helices that are arranged in greek key topology. Through their ability of forming 
homotypic interactions, they are widely found in inflammatory, apoptotic and 
necrotic signaling pathways15. 
1.7.1  Function of pyrin 
 
Figure 8: Function of pyrin. On the upper left:  The NLRP3 inflammasome is formed upon stimulus recognition 
by its LRR, therefore releasing the NOD domain, which now oligomerizes to form a multimeric assembly with 
ASC to activate procaspase-1. In the middle: Dimeric pyrin is shown in its auto-inhibited state through the 
intramolecular interaction between PYD and B-Box. Lower right: Pyrin can inhibit the maturation of pro-IL-1β 
by binding to NLRP3 inflammasome components as described in the text. Activation of pyrin can occur via 1) 
PAPA associated mutations in PSTPIP1. Wild type PSTPIP1 is binding to the PEST-type phosphaste keeping 
PSTPIP1 dephosphorylated. PAPA associated mutations interfere with the binding to the phosphatase, and 
as a result PSTPIP1 is phosphorylated and activates pyrin by binding to the B-Box. 2) Burkholderia 
cenocepacia infection also results in the formation of a pyrin inflammasome through a type-6 secretion system 
dependent mechanism. 3) The third activation mechanism is described via activated kinase p38α.  
 
A summary of the associated functions of pyrin is shown in figure 8.  
Through its association to FMF, pyrin was suggested to function in the innate 
immune signaling and therefore most studies elaborated pyrin’s contribution to this 
process. In yeast two-hybrid experiments, pyrin was shown to bind to the PYD 
domain of ASC through homotypic interactions104. The interaction seems to occur 
through the same interface as the NLRP3 PYD binds to ASC, as this interaction 
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can be competed with the pyrin PYD105. It was later found that pyrin can activate 
caspase-1 in a similar manner as described for NLRP3, by recruiting ASC and 
procaspase-1. The activation of caspase-1 by pyrin also resulted in the maturation 
of Il-1β and it was therefore postulated that pyrin can form an inflammasome as 
described for several NLRs106. Several mechanisms by which the pyrin 
inflammasome can be triggered were elucidated: 1) The Proline-Serine-Threonine 
Phosphatase Interacting Protein 1 (PSTPIP1) was shown to bind to pyrin in a 
phosphorylation dependent manner. PSTPIP1 is involved in cytoskeleton 
organization by forming filamentous networks107. Under normal conditions 
PSTPIP1 binds to rich in proline (P), glutamate (E), serine (S), threonine (T) protein 
threonine phosphatases (PEST-PTP) that keep PSTPIP1 dephosphorylated. The 
binding to the phosphatase is however altered in case of mutations in the PSTPIP1 
gene that are associated to another auto-inflammatory disease called pyogenic 
arthritis, pyoderma gangrenosum and acne (PAPA) syndrome108. In case of PAPA 
associated mutations, the binding ability of PSTPIP1 to PEST-PTP is reduced 
leading to an increased phosphorylation of the PSTPIP1. The phosphorylated form 
has an increased affinity to bind to the B-Box of pyrin. It is thought that this binding 
event leads to the release of the PYD domain from the B-Box and as a result 
activates pyrin109. Although it is not clear, whether PSTPIP1 induces pyrin 
activation in case of wild type PSTPIP1, it clearly shows the pro-inflammatory 
potential of pyrin. 2) Just recently, it was shown that an infection with Burkholderia 
cenocepacia (B.c.), a gram negative bacterium that resides within vacuoles of 
macrophages, leads to procaspase-1 activation and Il-1β maturation in a pyrin 
dependent manner. The exact stimulus (PAMP) of the bacterium was not found, 
but pyrin activation was dependent on the type 6 secretion system of B.c., 
suggesting that pyrin binds to a secreted bacterial protein. With confocal 
microscopy, it was shown that pyrin and ASC assembly around the vacuoles 
enclosing the B.c.110. 3) Another mechanism by which pyrin can be activated is 
through stress-induced activation of the mitogen-activated protein kinase (MAPK) 
p38111,112. By inducing ribotoxic stress that effectively activates (phosphorylates) 
the MAPK-p38, a pyrin dependent activation of procaspase-1 was observed. 
Interestingly, the MAPK-p38 is also activated by the signaling cascades induced 
by PRR, as described before.   
In contrast to the pro-inflammatory function that could be assigned to pyrin, it was 
also shown that pyrin can negatively influence the maturation of the pro-
inflammatory cytokine pro-IL-1β through inhibiting the NLRP3 inflammasome. 
Pyrin is recruited to NLRP3 through an interaction of its B30.2 domain and the NOD 
domain of NLRP3. In addition pyrin, was co-immunoprecipitated with active 
caspase-1, and the immature pro-IL-1β. Both interactions are also mediated by the 
B30.2 domain. Through the recruitment of pyrin to the inflammasome, and the 
binding capability to caspase-1 and pro-IL-1β, pyrin was shown to inhibit the 
maturation of the latter. However, the precise mechanism by which this inhibition 
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is mediated could not be assigned, but it was suggested that pyrin can inhibit the 
proteolytic activity of caspase-1. Additionally, due to the ability of pyrin’s PYD 
domain to compete with NLRP3 binding to the PYD domain of ASC, it was also 
assumed that the recruitment of pyrin to NLRP3 inhibits the recruitment of ASC to 
the inflammasome.  
Although pyrins interaction with caspase-1 was suggested to inhibit the protease, 
pyrin itself is a substrate of caspase-1. Pyrin is cleaved at aspartate 330. As a 
consequence of cleavage, the N-terminal product is capable of inducing NF-κB 
activation through inducing a proteosomal degradation of IκB, an inhibitor of NF-
κB. The N-terminal product was also shown to bind to the p65 subunit of NF-κB 
inducing its relocalization from the cytoplasm into the nucleus and induce gene 
transcription113. 
With respect to the FMF associated mutations, different results were obtained. It 
was suggested that the interaction to NLRP3-inflammasome components might be 
weakened, which would lead to increased pro-IL-1β maturation. The obtained 
results were contradictory. In one case, a FMF mutation did lead to a decreased 
binding to caspase-1 and therefore the amount of Il-1β was increased114. In another 
study, the mutation did not have a visible effect on either of the two events95. 
Despite the contradictory findings with respect to the binding of pyrin to caspase-1 
and pro-IL-1β, there seems to be an effect in case of the proteolytic cleavage of 
pyrin by caspase-1. Analysis of the state of pyrin from peripheral blood 
mononuclear cells revealed an increased amount of cleaved pyrin in FMF patients, 
suggesting that the N-terminal potential of NF-κB activation contributes to the 
disease symptoms113. 
1.7.2  FMF and pyrin 
More than 120 mutations have been identified in FMF patients (see Fig. 6; 
Infevers115). However the frequency is very heterogeneous. Mutations with highest 
frequency in FMF are M694V or M694I (together 52 %), M680I (13 %), V726A 
(13 %), E148Q (11 %), A744S (1.7 %), R761H (1.2 %)116-123. All other mutations 
are less abundant, although not in all studies has the whole MEFV gene been 
sequenced, leading to the possibility of having missed certain mutations. Note that 
besides E148Q, all mutations affect the B30.2 domain of pyrin. A genotype-
phenotype correlation can not be clearly assigned, as the phenotype not only 
depends on the mutation but is also influenced by other genes31. Some of the 
mutations also confer an atypical FMF phenotype.  
However, a homozygous M694V genotype was clearly associated to the 
development of amyloidosis, higher risk of arthritis and to an earlier onset of 
disease124,125. For the other mutations, a tendency for the associated severity of 
the phenotype can be postulated126. 
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1.7.3  Structure of pyrin 
At the beginning of this thesis, there was no structural information on pyrin. Several 
structures of homologous domains were solved, namely the PYD domain, B-Box 
and the C-terminal B30.2 domain. With respect to the TRIM motif, the only 
domain/motif, of which no structural information of any homologue is available, is 
the predicted coiled coil. However, as this central domain mediates oligomerization 
and is essential for function, this motif is of special interest as it is not known how 
TRIMs oligomerize and how the adjacent domains are connected to each other.  
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1.8 Aim of the work 
The association of pyrin to the disorder FMF reveals its importance in the 
modulation of an innate immune response. The many studies performed in-vivo 
elucidated the ability of pyrin to modulate the maturation of the proinflammatory 
cytokine pro-IL-1β. However, the mechanism by which pyrin can either act in a pro-
inflammatory inflammasome like manner, or inhibit the activity of NLR-
inflammasomes is not known. This is partly due to the complexity of the innate 
immune system, but also due to the lack of structural information and 
understanding of the interactions in which pyrin is involved in on a molecular level. 
At the start of thesis, all interaction studies regarding pyrin were done in vivo. 
Besides the many advantages of in-vivo studies, it was shown to be very 
challenging to study the effect of FMF related mutations on the binding behavior of 
pyrin. Additionally, the lack of structural information makes it difficult to predict 
domain boundaries that can be used to rationally design deletion mutants for in-
vivo studies. This is not only true for pyrin, but also for the whole class of TRIM 
proteins, where only single domains of a few members have been solved. 
The first aim of this thesis was therefore to structurally characterize pyrin or 
fragments of pyrin to obtain a structural understanding of pyrin and TRIM proteins 
on a molecular level. As most FMF related mutations are clustered in the B30.2 
domain, and the fact that for this domain several binding partners were identified, 
we had a clear focus on this domain. By rational design of N-terminal deletion 
mutations, we aimed to identify stable pyrin fragments suitable for X-ray 
crystallography and in-vitro binding studies. In this thesis, we could solve two 
crystal structures of C-terminal fragments of pyrin. As described in the first 
publication we solved the structure of the B30.2 domain. We subsequently aimed 
to analyze the structural features of several FMF related mutants found in this 
domain which is summarized in the 2nd manuscript. However binding studies using 
the single B30.2 domain were not successful. 
As all TRIM proteins oligomerize, we designed larger constructs that included the 
predicted coiled coil motif. As the minimal dimeric construct of pyrin (pyrinΔ413) 
was best expressed, we used this CC-B30.2 construct to establish binding assays 
and gather further structural information. The final aim was to characterize the 
effect of FMF related mutations on the effect of ligand binding. 
The structure determination of the dimeric pyrin construct showed for the first time, 
how TRIM proteins mediate dimerization and how all domains are arranged in the 
full length protein. We also established quantitative and qualitative binding assays 
to test the interaction of pyrin to pro-IL-1β. These results are summarized in the 3rd 
manuscript.  
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Abstract 
Familial Mediterranean Fever (FMF) is a recessively inherited auto-inflammatory 
disorder characterized by recurrent episodes of fever. The gene responsible, 
MEFV, encodes a 781 amino acid multi-domain protein called pyrin/TRIM20. 
Throughout the gene more than 120 FMF related mutations have been identified, 
however the most frequently occurring mutations reside in the C-terminal B30.2 
domain that acts as a ligand binding domain. Structures of homologous B30.2 
domains in complex with ligands revealed their common binding epitope created 
by variable loops and an enclosed cavity on the concave β-sheet. Residues 
creating this putative binding interface in pyrin are frequently mutated in FMF 
patients suggesting an alteration of the binding mode of the pyrin B30.2 domain. 
To elucidate the structural consequences induced by FMF related mutations, we 
have determined the crystal structures of five mutants. We focused on mutations 
positioned in one variable loop as well as on mutations on the β-sheet where the 
most prominent mutation, M694V, is located.  
The mutations do not lead to changes in the overall structure of the B30.2 domain 
but manifest in local changes of the binding interface. Mutations located on the β-
sheet lead to a reshaped central cavity and changes in the electrostatic surface 
potential of the epitope. Mutations found within the variable loop-5 affect the 
conformational flexibility of loop-5 and the adjacent loop-2. Whereas the mutation 
M680L stabilizes loop-5 in a distinct conformation the mutation G678V reveals the 
importance of a hydrogen bond network formed between loop-2 and -5. Once the 
network is broken loop-2 experiences a greater flexibility, disclosing the possibility 
of a communication between the loops. 
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Introduction 
The autosomal recessive disorder Familial Mediterranean Fever (FMF) is 
characterized by recurrent episodes of fever, usually accompanied with serositis in 
the peritoneum, pleura and synovium1. The self-limiting attacks normally last for 12 
to 72h and are intermitted by symptom-free periods of weeks to months. FMF is 
mostly found in ethnics around the Mediterranean basin, namely Jews, Armenians, 
Turks and Arabs2. If untreated with colchicine, FMF patients can develop 
amyloidosis which eventually leads to renal failure1. In 1997, two FMF consortia 
have identified the gene responsible for FMF, MEFV3,4. The 3.5kb gene is located 
on chromosome 16 consisting of 10 exons and encodes a 781 amino acid protein 
that was named pyrin. A growing number of FMF associated mutations have been 
identified throughout the gene, however the most frequent mutations are clustered 
in exon 105-12. 
Pyrin is a multidomain protein that belongs to the tripartite motif-containing (TRIM) 
family of proteins, and is therefore also called TRIM2013. As most TRIM proteins, 
pyrin contains a C-terminal B30.2 (PRYSPRY/SPRY) domain that in case of pyrin 
is encoded by exon 1014. Two opposing functions are suggested for pyrin, namely 
the inhibition and activation of innate immune signaling.  
The recognition of danger associated molecular patterns (e.g. , extracellular ATP 
or reactive oxygen species) by the NOD-like receptor NLRP3 triggers the formation 
of a large cytoplasmic complex called NLRP3-inflammasome15. This complex 
leads to the activation of the inflammatory protease caspase-1 that subsequently 
cleaves Pro-Interleukin-1β (pro-IL-1β). Mature IL-1β is secreted and acts a major 
pro-inflammatory cytokine16. Through its B30.2 domain pyrin can interact both with 
caspase-1 and pro-IL-1β thus inhibiting IL-1β maturation17. 
In certain cellular challenges pyrin can act alone as an inflammasome and initiate 
the maturation of IL-1β18-22. The formation of a pyrin inflammasome can be induced 
by disease associated mutants of the Proline-Serine-Threonine Phosphatase 
Interacting Protein 1 (PSTPIP1), a Burkholderia cenocepacia infection or by 
ribotoxic-stress. As for NLRP3, the formation of a pyrin inflammasome leads to 
caspase-1 activation and IL-1β maturation. The effect of FMF related mutations in 
pyrin in either anti- or pro-inflammatory function has not been elucidated or is 
contradictory (see references above). 
As the most frequent mutations occurring in FMF are clustered in the C-terminal 
B30.2 domain, we have recently determined its crystal structure to identify the 
locations of the mutations and provide a structural basis for the mutant effect23. 
The B30.2 domain of pyrin folds into two antiparallel β-sheets which are connected 
in a jellyroll like topology, as seen for all B30.2 domains24-27. The variable loops 
and the enclosed central cavity were shown to create the domain typical binding 
epitope and confer the specificity for ligand binding24,29,30. Mapping the FMF 
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associated mutants on the pyrin B30.2 structure showed that most of them 
superimpose with the commonly found epitope and define a putative binding 
interface for pyrin23. This includes two hotspots where mutations are associated to 
a severe phenotype. One hotspot is the methionine 680 (M680) located in loop-5, 
which has been found to be mutated to isoleucine or leucine (M680I,L) in about 
13% of the sequenced alleles of FMF patients6-12,28. The second hotspot harbors 
the most frequently mutated residue methionine 694 (found in over 50% of the 
alleles) and resides in β-strand 6 located at the rim of the central binding cavity. 
Mutations of M694 to valine, leucine, isoleucine or a deletion (M694V,I,L,del) are 
all associated with FMF, where the mutant M694V is associated to a severe 
phenotype with increased risk of developing amyloidosis, the most severe effect of 
FMF which can ultimately lead to renal failure29,30. 
In order to elucidate the structural changes in these two hotspots that confer a FMF 
phenotype, we have solved the crystal structures of several FMF related mutants, 
namely G678V, M680L, I692del and M694V. The mutant structures reveal the 
distinct kind of alterations that lead to modifications in the binding characteristics 
of the pyrin B30.2 domain. 
Materials and Methods 
Expression and purification of B30.2 domain mutants 
Mutants were generated using QuikChange mutagenesis (InvitrogenTM, United 
States) using the previously reported construct of the pyrin B30.2 domain (coding 
for residues 578-781) in a pGEX-6P-1 vector (GE Healthcare, United States)23. 
Correct mutagenesis was confirmed by DNA sequencing. The mutants were 
expressed as a GST-fusion protein and purified as described23. Briefly, the mutants 
were expressed in Escherichia coli BL21(DE3) cells. Cultures were grown to an 
OD600nm of 0.6 at 30 °C and protein expression was induced with 0.1 mM or 0.5 
mM IPTG for mutants I692del, M694V and R653H, G678V, M680L, respectively. 
The expression was carried out at 18 °C for 18 h. Cells were harvested (4000 g, 
20 min) and the pellet resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 300 mM 
NaCl, 20 mM NaH2PO4, DNase 1, 0.5 mg/ml lysozyme) and lysed using an Emulsi-
Flex C3 homogenizer (Avestin, Canada). The lysate was cleared by centrifugation 
(20 000 g, 45 min) and the fusion protein extracted from the soluble fraction using 
a GSTrap 4B affinity chromatography column (5 ml; GE Healthcare, United States) 
according to the manufacturer’s protocol. The fusion protein was digested by 
incubation with recombinant/GST-tagged PreScission Protease (GE Healthcare) 
and simultaneous dialysis against PreScission protease cleavage buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5 mM TCEP), followed by 
reapplication onto a GSTrap 4B affinity column to remove the GST and protease. 
The mutants were further purified by anion exchange chromatography 
(Resource™ Q, 10 mM Tris-HCl pH 9.0, 0.5 mM TCEP, 1 % (v/v) glycerol, gradient 
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from 0 to 500 mM sodium chloride), and the oligomeric state was analysed using 
a Superdex 75 10/300 size exclusion chromatography column (GE Healthcare; 50 
mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM TCEP, 10 % (v/v) glycerol). 
Crystallisation and structure determination 
All mutants were concentrated to 10 mg/ml and crystallized using the sitting drop 
vapour diffusion method. The crystallisation conditions for R653H, G678V, M680L, 
I692del and M694V were [0.1 M Na-Acetate, pH 5.5. 0.2 M KSCN, 25 % (w/v) PEG 
2k MME, 4 °C], [0.1 M Tris-AcOH, pH 7.4, 0.2 M KSCN, 23.3 % (w/v) PEG 2k MME, 
20 °C], [0.1 M Tris-AcOH, pH 8.0, 0.2 M KSCN, 23.3 % (w/v) PEG 2k MME, 20 °C], 
[0.1 M Tris-AcOH, pH 7.6, 0.2 M KSCN, 30 % (w/v) PEG 2k MME, 20 °C] and [0.1 
M Tris-AcOH, pH 7.5, 0.2 M KSCN, 25 % (w/v) PEG 2k MME, 20 °C], respectively. 
Prior to freezing the crystals were briefly soaked in a cryoprotectant solution 
consisting of the mother liquor supplemented with 10 % ethylene glycol. Native 
data sets of the mutants were recorded at the X06SA or X06DA beamline at the 
Swiss Light Source (PSI, Villigen, Switzerland). While the mutants G678V, I692del 
and M694V crystallized in the same space group as the wild type (P6522), mutants 
R653H and M680L crystallized in space group P212121. Data were indexed, 
integrated and scaled with XDS31. For mutants R653H and M680L, molecular 
replacement was performed using Phaser with the wild type structure as search 
model32. Structures were refined using Phenix and Refmac and manually edited 
using Coot33-35.  
Structure analysis 
Structures were analysed with the in-built structure comparison tool in Phenix. The 
electrostatic surface potential was created using the Adaptive Poisson-Boltzmann 
Solver plugin (version 2.0) implemented in PyMOL (Schrödinger, LLC)36. PQR files 
were generated using the PDB2PQR server37. 
Sequence alignment 
Sequences used correspond to the UniProt entries O15553, Q9C035, Q9C029, 
P19474, Q8IYM9, P14373, Q8NG06, Q9BVG3 and Q86WT6 for pyrin, TRIM5α, 
TRIM7, TRIM21, TRIM22, TRIM27, TRIM58, TRIM62 and TRIM69 respectively. 
Alignment was generated using T-coffee38 and Jalview39. 
Results 
We solved the crystal structure of the mutants R653H, G678V, M680L, I692del and 
M694V (see Fig. 1). All mutants displayed monomeric behavior when analyzed by 
size exclusion chromatography (data not shown). Whereas the mutants M694V, 
I692del, and G678V all crystallized in the same space as the wild type, namely 
P6522 the mutants R653H and M680L crystallized in space group P212121 (for data 
collection and refinement statistics see Suppl. Table1+2). Both crystal forms 
contained one molecule in the asymmetric unit. The achieved resolutions for the 
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structures are between 1.5 Å for the R653H mutant and 2.4 Å for the G678V 
mutant. The overall structural changes are small with root mean square deviations 
(rmsd) of the backbone between 0.163 Å for the M694V mutant and 0.482 Å for 
the I692del mutant (see Suppl. Table 2). 
Mutations within loop-5 
In the previously determined wild type structure loop-5 (loop-5-wt) was weakly 
defined and could not be traced in a defined conformation, which is attributed to its 
flexibility23. A mutation distantly located from loop-5 is R653H. However, loop-5 of 
this mutant structure (loop-5-R653H) is present in a distinct conformation which is 
probably due to the crystallization of the mutant in P212121 compared to P6522 for 
the wild type (Suppl. Fig. 1A+B). Nevertheless loop-5-R653H still shows a 3-fold 
increased temperature factor (i.e. flexibility) compared to the mean temperature 
factor of the whole molecule confirming the intrinsic flexibility of this loop.  
The mutant structure of the hotspot mutation M680L, residing in loop-5, also 
crystallized in space group P212121 and is therefore compared to loop-5-R653H. 
The mutation of M680L leads to a different orientation of the side chain of residue 
680 with consequences for the entire loop-5 (see Fig. 2A). While the wild type M680 
is pointing into the solvent and is flexible, L680 points towards a hydrophobic patch 
created by residues F636, I641 of loop-2 and I674, L682 and Y688 of loop-5. The 
packing of L680 into the hydrophobic patch results in a defined rotamer of the side 
chain, as manifested by its well defined electron density and to significant lower 
temperature factors of loop-5-M680L compared to loop-5-R653H (see Fig. 2E and 
Suppl. Fig. 1B+C). The different orientation of the leucine side chain compared to 
the wild type methionine also leads to small differences of backbone trace for 
residues K677 to T681.  
Notably, both the side chain of L680 and the backbone of the entire loop-5-M680L 
adopts a similar conformation as the corresponding F369 and loop-5 in the 
structure of the ligand bound B30.2 domain of pyrin homologue TRIM21, in which 
the side chain also orients towards the hydrophobic patch (see Fig. 2B).  
The differences between loop-5 in the two different space groups are small, but 
loop-5-R653H and loop-5-M680L form a larger and more defined hydrogen bond 
network with loop-2 (see Fig. 2C). Residues R676, K677 and G678 of loop-5 form 
hydrogen bonds through their side and main chain atoms to residues of loop-2 with 
a coordinated water molecule between the loops. The involved residues in loop-2 
(G632-C639) contribute almost exclusively with their backbone atoms to the 
hydrogen bond network. Loop-5-wt differs most in the position of G678, which can 
not be localized in the wild type and therefore does not contribute to the hydrogen 
bond network. Also K677 and the coordinated water are less well defined 
compared to the mutant structures (see Suppl. Fig. 1A-C). A possible consequence 
of the enlarged hydrogen bond network in the mutant structures is the stabilization 
of loop-2 as seen by its improved definition of the electron density compared to the 
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wild type (see Suppl. Fig. 2). A detailed summary of the hydrogen bond network is 
given in the Supplementary Information which also includes the B30.2 domain of 
TRIM21, where the same hydrogen bond network is seen (see Suppl. Table. 3)25. 
Additionally, the RKG motif of loop-5 is conserved among some members of the 
TRIM family (Suppl. Fig. 3). 
In both space groups, the Φ and Ψ angles of G678 of the RKG motif are in a 
Ramachandran plot region which is not allowed for non-glycine residues. The 
mutation of this residue to valine (G678V) is rare but associated to FMF (Infevers 
registry5). Similar to the wild type structure, loop-5 is weakly defined revealing that 
a hydrophobic residue at this position, compared to residue 680, does not alter the 
flexibility of loop-5. In comparison to loop-5-wt, there is no electron density seen 
for the side chain of R676. However the backbone of loop-5 can be traced at a 
lower σ-cutoff of 0.8. Through the mutation to valine, whose Ramachandran 
restraints are more limited, the backbone conformation for residues V678 and 
N679 is changed (see Fig. 3A). The two residues are further apart from loop-2 and 
point into the solvent leading to a complete loss of the hydrogen bonds between 
loop-2 and -5 also lacking the coordinated water molecule. The lack of interaction 
between both loops results in a destabilized loop-2 with no apparent electron 
density for residues 626-634. Also residues 639-634 show an increased flexibility 
in the G678V mutant structure as judged from the increased temperature factors 
for these residues as compared to the wild type (see Fig. 3B). This is particularly 
pronounced for the phenylalanine at position 636. This residue is part of the 
aforementioned hydrophobic patch formed between the two loops and is a highly 
conserved residue in the B30.2 domain of TRIM proteins (see Suppl. Fig. 3). These 
results suggest that the RKG motif is an important motif to stabilize loop-2, and that 
this stabilizing effect is lost in case of a G678V mutation. 
Mutations in β-strand 6 
The second hotspot region associated with FMF is β-strand 6 (β-6) located on the 
concave surface of the β-sandwich. This strand is creating the rim of the central 
cavity in the putative binding interface. In the B30.2 domain of TRIM21, residues 
of β-6 are key residues in the interaction with the IgG25. In pyrin, a mutation of 
M694 to valine induces a strong phenotype and is correlated with the development 
of amyloidosis. Structurally, the mutation exhibits the smallest changes among all 
studied mutants with an rmsd of the backbone of 0.163 Å compared to the wild 
type. The mutation to valine induces structural changes that are limited to the side 
chains of residues 694, 695 and 698 (see Fig. 4A). While in the wild type the longer 
M694 is pointing into the central cavity, the Cγ1 of the Cβ-branched valine is 
directed towards K695 that introduces minor changes in the neighboring residues. 
The side chain of K695 is flexible in the wild type structure. In the M694V mutant 
structure the lysine side chain seems to be stabilized as its position is defined by 
the experimental electron density. The same effect is seen for the glutamate 698, 
which side chain is clearly defined in the M694V mutant (not illustrated). Due to the 
Manuscript: Structural consequences of FMF associated mutations in the pyrin B30.2 domain. 
 
57  
smaller valine in the M694V mutation the central binding cavity becomes slightly 
larger but no apparent changes in the electrostatic surface potential are seen (see 
Fig. 4C). The severity of the associated phenotype compared to small local 
changes suggests that M694 is a key residue in the interaction with pyrin’s putative 
ligand. 
As M694, I692 is located in β-6 (res. 687-695), which runs antiparallel to β-7. The 
I692del mutation induces a register shift of one amino acid, by pulling residues C-
terminal of V691 in the N-terminal direction (see Fig. 4B). The analysis of the 
hydrogen bonds present between β-6 and β-7 reveal that the register shift is limited 
to β-6. Whereas in the wild type the E698 of β-7 forms an “irregular” hydrogen bond 
pattern with both the amide of M694 and the carbonyl of K695, it forms both 
hydrogen bonds to the lysine residue (K694) in the deletion mutant creating a 
hydrogen bond pattern typical for anti-parallel β-sheets. As a consequence β-6 is 
shortened by one residue and the adjacent β-turn is positioned closer towards the 
central cavity. The sequence of the β-6 is changed from Ile-Met-Met-Lys (res. 692-
695) in the wild type to Met-Met-Lys (res. 692-694) in the deletion mutant. The 
resulting changes in the surface exposed side chains and the shortening of the β-
6 have an impact on both the shape and the electrostatic surface potential of the 
central cavity. The pronounced rim created by M694 is lost and the central cavity 
reshaped. In addition, through the replacement of the hydrophobic M694 by a 
charged lysine the rim of the central binding pocket becomes more positively 
charged (see Fig. 4C). The I692del mutation also resembles anM694del mutation 
because the β-6 gets shortened by this specific residue. 
Local effects of the R653H mutation 
Although not located in the putative binding interface a R653H mutation confers a 
mild phenotype. An arginine at this position is rather rare throughout the B30.2 
domains of TRIM proteins, while a histidine at this position is conserved (see Suppl. 
Fig. 3). The shorter histidine at this position leads to the loss of a hydrogen bond 
to S650 (see Fig. 5A). The wild type arginine binds through its guanidinium group 
both to the carbonyl oxygen as well as to the hydroxyl oxygen of S650. The 
histidine only mediates a hydrogen bond to the main chain oxygen. A probably 
larger effect of this mutation is the resulting change in the electrostatic surface 
potential. Whereas the arginine is positively charged, the histidine is negatively 
charged at physiological conditions (see Fig. 5B). 
Discussion 
The B30.2 domains are protein binding domains that interact with various different 
targets41. The common binding interface is defined by variable loops enclosing a 
central binding pocket, which confers the ligand specificity for each B30.2 domain. 
As most of FMF associated mutations map to the common binding interface, it is 
thought that these mutations alter the binding behavior of the B30.2 domain to its 
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ligand(s). Due to the severe phenotype associated with different mutations, two 
hotspot regions within this interface have been postulated29. 
We solved the crystal structure of five B30.2 domain mutants, which are associated 
with an FMF phenotype. Their structural changes are local such as changes in the 
shape of the central binding cavity (I692del, M694V) and alterations in the 
electrostatic surface potential (I692del, R653H) but also affect entire loops in their 
flexibility (M680L) as well as conformation (G678V). 
The hotspot mutation in loop-5, M680L, rigidifies the loop it is positioned in through 
the binding of the leucine side chain to the hydrophobic patch between loops -2 
and -5. The same effect can be suggested for the more often occurring FMF mutant 
M680I. The loop-5 of TRIM21 has similar characteristics as found in the pyrin 
M680L mutant by having a stable conformation of this loop. As the B30.2 domain 
of TRIM21 is thought to bind to the IgG in a lock-and-key mode, i.e. without 
undergoing large structural changes upon ligand binding, a rigid loop conformation 
is probably a prerequisite for high affine binding26,42. In wild type pyrin however this 
loop requires some conformational flexibility for its correct function, which is 
altered.  
Our mutant study reveals the importance of the interactions between loop-2 and 5. 
Both mutants that crystallized in space group P212121 show a well defined 
hydrogen bond network between these two adjacent loops that involves the 
residues RKG of loop-5. This network of hydrogen bonds is also seen in TRIM21, 
and judging from the sequence alignment is probably also present in homologous 
B30.2 domains due to the conservation of the amino acids RKG. By disrupting the 
hydrogen bond network created by the RKG motif in loop-5, loop-2 can be 
markedly affected and becomes more flexible as seen in the G678V mutant 
structure. Through a conformational change of loop-5 the interactions to loop-2 are 
lost resulting in an increased flexibility of loop-2 that is partly not traceable in the 
crystal structure of the G678V mutant. The loss of interaction between the loops 
also results in an increased mobility of phenylalanine 636 that is part of the 
hydrophobic patch between the loops. This phenylalanine has been suggested to 
play a crucial role in hooking loop-2 to the compact B30.2 domain fold, as its 
replacement from the hydrophobic patch between loop-2 and -5 leads to very 
mobile loop-2 as seen in the structure of the rhTRIM5α B30.2 domain (Ivanov, Cold 
Spring Habor Meeting on Retrovirus, 2013)26. In summary, the conserved RKG 
motif and the participation of F636 in the hydrophobic patch lead to a distinct 
conformation of loop-2 and -5.  
With respect to the effect of the FMF mutation G678V in pyrin, two plausible 
consequences can be suggested. First, the conformational space for loop-5 is 
altered due to the restriction of valine with respect to the backbone dihedral angles, 
therefore altering the contribution of this loop to ligand binding. A second 
consequence could be the increased flexibility of loop-2. Although no severe 
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mutations are located in loop-2, it contributes to the binding in case of TRIM5, 
TRIM21 and also in the further distant related B30.2 like domain (SPRY domain) 
of GUSTAVUS44 and changes in the flexibility of loop-2 of pyrin might change the 
binding affinity. 
Due to the intrinsic flexibility of loop-5 in pyrin as seen in the wild type structure 
and its putative involvement in ligand binding, a possible communication between 
these loops can be suggested. One can imagine that upon ligand binding loop-5 is 
rearranged in such a way that a change in the hydrogen bond network is induced, 
resulting in a greater flexibility of loop-2. The reduced intrinsic flexibility in case of 
the M680L mutant might inhibit such a communication. As a methionine at this 
position is thought to have evolved during evolution43, this might also introduced a 
possible communication between the loops. 
M694V harbors one of the most abundant mutations in FMF patients and is 
associated to a severe phenotype. However, the changes in the M694V mutant are 
very subtle. The exchange from methionine to valine only affects the side chain of 
this residue. As the residue 694 is creating a rim of the central cavity, a M694V 
mutation alters the shape of the central cavity. This suggests that the side chain of 
M694 is crucial for the interaction of pyrin with its ligand probably because it is 
directly involved in the interaction as observed for the corresponding residue in 
TRIM21. 
A larger influence is seen for the I692del mutant due to the shortening of β-6. This 
mutation is considered to confer mild FMF symptoms29. As the M694 seems to be 
crucial for a correct function of pyrin, the effect of the mutation is probably exerted 
by the exchange of M694 by R694 with the resulting change in the shape and 
electrostatic surface potential of the central cavity. In this mutant the β-6 is 
shortened by residue 694, therefore a similar effect can be suggested for the 
M694del mutant, which would again lead to an lysine residue at position 694. This 
mutant is associated with a severe phenotype and, apart from still containing the 
native isoleucine at position 692, is probably structurally highly similar to the 
I692del29.  
A residue not superimposing with the reported binding interfaces of other B30.2 
domains is R653. However, a mild phenotype is associated with mutations at this 
position, suggesting that the pyrin B30.2 domain has more than one binding 
interface7,23,40. Interestingly, only human, gorilla and chimpanzee carry an arginine 
at this position, while other primates carry a conserved histidine43. The same is 
true for B30.2 domains of human TRIM proteins, where a histidine is conserved. 
The R653H mutant shows the same local structural features as TRIM5α, which has 
a histidine at this position. The major effect of this mutation is a change in the 
electrostatic potential that might alter the interaction with a ligand. However, no 
specific function for the histidine or arginine at this position has not yet been 
assigned in any B30.2 domain. 
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Several binding partners are proposed for the B30.2 domain, including pro-IL-1β, 
caspase-1 and the nucleotide-binding domain of the NLRP1-317,45. Pyrin has also 
been associated to both anti- as well as pro-inflammatory functions and it is 
therefore hard to speculate about the precise effect of the mutants on function. 
However, our data reveal that the structural changes induced by FMF associated 
mutations locally affect the shape of the central cavity, but also alter the 
conformational flexibility of entire loops. For a correct binding mode of the B30.2 
domain of pyrin, not only the shape of the cavity in crucial, but also a flexible loop-
5 and a stabilized loop-2 are prerequisites for ligand binding. 
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Figures legends 
Figure 1 
The B30.2 domain is shown in a cartoon representation. The positions of the 
mutations, of which the crystal structures have been determined in this study, are 
indicated by orange spheres. The affected loops and β-sheets are labeled 
according to Weinert et al.23. Structural elements labeled in red indicate their 
involvement in putative ligand binding. The chosen perspective serves as a 
reference for subsequent figures. 
Figure 2 
Stereo representation of the structural features of loop-5 shown for the individual 
mutants M680L and R653H: A) The mutant M680L crystallized in the same space 
group as R653H. Both structures are superimposed and presented in the 
orientation as indicated in D. The R653H and M680L mutant structures are shown 
in purple and orange stick, respectively. Only hydrogen bonds between loop-2 and 
-5 that are found to be different are indicated in dashed lines according to the color 
of each mutant structure. B) The mutant M680L was superimposed with the B30.2 
domain of TRIM21 that was solved in complex with an IgG (pdb-code: 2iwg). The 
M680L is colored as in A and the TRIM21 B30.2 domain in white sticks. The 
coordinated water (red sphere) and the hydrogen bond network (dashed lines) are 
shown only for the M680L mutant, but are comparable for TRIM21 C) The 
conformation of loop-5 and the adjacent loop-2 of mutant R653H is superimposed 
with the wild type structure. Both structures are shown in a stick representation and 
colored green and purple for the wild type and the R653H mutant, respectively. 
Hydrogen bonds found in the R653H mutant are indicated as black dashed lines. 
The coordinated water molecule is shown as a red sphere. For simplicity only one 
of the two conformations seen in the wild type structure is presented. D) Standard 
view of the B30.2 domain as in Figure 1. The residues depicted in Fig.2 A-C are 
colored in orange and the chosen viewpoint is indicated. E) Normalized B-factors 
of the protein backbone are shown for residues of loop-5 of mutants R653H 
(resembling the wild type) and M680L in purple and orange, respectively. 
Figure 3 
Structural effects of the G678V mutation. A) Superimposed loop-5 and loop-2 are 
shown in a stereo representation for the wild type and the G678V mutant structure 
in green and in orange, respectively. B) The normalized B-factors are plotted in 
green and orange for loop-2 residues of the wild type and G678V, respectively. 
Indicated is the position of the Phe636 that plays a crucial role for the fixation of 
loop-2. Residues 626-633 could not be traced in the electron density of the G678V 
mutant structure. The view is identical as in Figure 2. 
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Figure 4 
Structural features of mutations in β-strand 6: A) Stereo view of the M694V mutant 
structure compared to the wild type is shown for β-strand 6 and 7 in a stick 
representation. Wild type and M694V mutant are colored green and orange, 
respectively. B) The same close up view of β-strand 6 and 7 for superimposed wild 
type and I692del mutant structure colored in green and orange, respectively. The 
hydrogen bond network between the two strands is indicated by dashed lines in 
the corresponding color and schematically illustrated on the right. C) The 
electrostatic surface potential for wildtype, M694V and I692del mutant structures 
are displayed between -5 kT/e and 5 kT/e. 
Figure 5 
Structural and electrostatic changes introduced by the R653H mutation. A) Loop-
3 is superimposed and illustrated in green and orange sticks for the wild type and 
the R653H mutant, respectively. The hydrogen bonds between Ser650 and R653 
or H653 are indicated by dashes in the according color. B) The change of the 
positively charged arginine to the more negatively charged histidine is visualized 
by the electrostatic surface potential of wild type (on the left) and mutant (on the 
right) between -5 kT/e and 5 kT/e. On the right, residues depicted in A are colored 
orange and the chosen viewpoint indicated. 
Supplememtary Figure 1 
Changes in the electron density of loop-5. Loop-5 of wild type (2wl1) (A), the R653H 
(B) and M680L (C) structure are shown in sticks in green, purple and orange, 
respectively. In all structures the electron density for residues 674-684 is displayed 
with a σ-cutoff of 1.5 rmsd. The view is similar as in Figure 2. 
Supplememtary Figure 2 
Differences in the observed electron density for loop-2. Residues 622-636 are 
shown in sticks and their corresponding electron density displayed with a σ-cutoff 
of 1.0 rmsd. Wild type, G678V, M680L and R653H are colored green, orange, 
orange and purple, respectively. The orientation of the B30.2 domain is as 
displayed in Figure 1. 
Supplememtary Figure 3 
Sequence alignment of the B30.2 domains of different human TRIM proteins. 
Secondary structure elements are assigned according to Weinert et al.23. Residues 
are shaded according the BLOSUM62 score between white and blue from no 
conservation to full conservation, respectively. The alignment in ordered according 
to the sequence similarity to pyrin. Highlighted in red boxes are the amino acids 
involved in hydrogen bonding between loop-2 and 5 in the pyrin B30.2 domain. 
Residues involved in hydrophobic interaction between the loops are marked in red. 
The R653 forms two hydrogen bonds to the S650, whereas H653 only bonds to 
the carbonyl oxygen of the serine residue. These residues are highlighted by a 
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grey box, also showing that a histidine at this position is conserved in most TRIM 
proteins.  
Supplememtary Table 1 
Data Collection Statistics. 
Supplememtary Table 2 
Refinement Statistics 
Supplememtary Table 3 
Hydrogen bonding network between loop-2 and loop-5. 
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Abstract 
Tripartite motif-containing (TRIM) proteins comprise a RING finger, a B-Box, a 
predicted coiled coil here termed central helical scaffold (CHS) domain and in most 
cases a C-terminal B30.2 domain. So far the overall architecture of TRIM proteins 
is unknown since only structures of individual domains are available. Here we 
present the 2.4 Å crystal structure of a functional portion of TRIM20 consisting of 
the CHS and B30.2 domains. In contrast to the previously assumed parallel 
arrangement, two CHS domains arrange in antiparallel manner thereby forming 
elongated dimers with centrally positioned B30.2 domains and B-Boxes placed 
distal 170 Å apart. Interdimeric contacts between B30.2 and CHS domains 
construct a yet unknown TRIM tetramer and unveil the mechanism of higher order 
self assembly. Together with the full length model, our data provides 
unprecedented insights into the structural and functional modularity of these 
proteins.  
Significance statement 
TRIM proteins are involved in various processes that include regulation of the 
innate immune response. Despite their functional diversity they share a common 
domain architecture. A striking feature is their ability to form higher order self-
assemblies that in case of TRIM5 creates a hexagonal lattice. However, due to the 
lack of high resolution structures, the connectivity of the domains as well as a 
precise model of higher order assemblies remained unknown. We present the first 
crystal structure of a functional TRIM20 C-terminal fragment that reveals the 
antiparallel mode of dimerization as well as how two dimers form a tetramer. The 
presented structure not only allows modeling a full length TRIM protein, but also a 
precise model of a TRIM lattice.  
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Introduction 
Tripartite motif-containing (TRIM) proteins represent a large family of proteins 
comprising approximately 100 human members, linked to diverse cellular functions 
including regulation of the innate immune system, retroviral restriction, cell 
proliferation and differentiation (1, 2). They share a conserved domain architecture 
consisting of an N-terminal RING domain, one or two B-Box domains followed by 
a predicted coiled coil motif here called central helical scaffold (CHS) domain (3). 
The RING and B-Box domains are zinc fingers that confer E3-ligase activity and 
protein-protein interactions to form higher order oligomers (HO), respectively (2, 4-
6). The B-Box is followed by the CHS domain, which is responsible for low order 
oligomerization (3). C-terminal of the CHS domain about half of the TRIMs contain 
a B30.2 domain that mediates ligand binding (7-9).  
TRIM20, also named pyrin, has an N-terminal pyrin domain (PYD) and a linker 
region of unknown structure, preceding a degenerated RING sequence (10). The 
PYD belongs to the death domain superfamily enabling homotypic interactions with 
other PYD containing proteins (11, 12). TRIM20 is involved in the modulation of 
the pro-inflammatory cytokine pro-Interleukin-1β (pro-IL-1β) and is associated to 
the auto-inflammatory disease Familial Mediterranean Fever (FMF) (13, 14). 
Through a direct interaction to pro-IL-1β, TRIM20 is considered to inhibit the 
inflammasome mediated maturation of the cytokine (15). However, TRIM20 can 
also potently induce the maturation of pro-IL-1β (6, 16-18). The exact mechanism 
of regulation between these two contrary functions is not known. 
Several structures of isolated RING, B-Box and C-terminal domains of TRIM 
proteins are known to date (5, 19, 20). With respect to the TRIM tripartite motif 
(RING, B-Box and CHS domain), the CHS is the only domain where no structural 
information exists so far. This domain is of particular interest as it defines the spatial 
arrangement of the adjacent domains and thus the overall architecture of TRIM 
proteins.  
Within the CHS sequence a coiled coil (CC) motif and an L2 linker to the B30.2 
domain is predicted (21). The CC motif is prognosticated within the first 100-120 
amino acids C-terminal of the B-Box and the adjacent L2 linker is between 50 to 
70 amino acids in length (22). For the retroviral restriction factor TRIM5α and the 
intracellular Fc-receptor TRIM21, the CHS domain is responsible for dimerization 
(23-25). This formation of low order oligomers is essential for function as in both 
TRIM20 and TRIM5α a deletion of the CHS results in a monomeric and inactive 
protein (6, 26). However, dimerization does not seem to be the only function of the 
CHS. In addition, residues have been identified in the CHS domain of TRIM5α that 
do not interfere with dimerization, but lead to a loss of restriction (27). 
Here we present the crystal structure of a functional part of TRIM proteins, the 
TRIM20 CHS-B30.2 C-terminal portion, providing insight into the overall structure 
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of TRIM proteins. Using small angle X-ray scattering (SAXS) we revealed the 
flexibility between the CHS and the B30.2 domains mediated by a short hinge. In 
addition, we characterized the binding of the CHS-B30.2 fragment to pro-IL-1β in 
vitro.  
Results 
Crystal Structure of TRIM20Δ413. To investigate the mode of oligomerization 
and the relative arrangement of the B30.2 domain in TRIM proteins we designed a 
construct that comprises the CHS and the B30.2 domains. Secondary structure 
prediction for TRIM20 suggests that the bipartite CC motif of the CHS starts shortly 
after the B-Box domain (Fig. S1). We therefore engineered a construct that starts 
with the conserved glutamate 414 yielding a fragment called TRIM20Δ413 (Fig. 
1A). Analytical ultracentrifugation at 4 °C shows that this C-terminal fragment is a 
dimer in solution (Fig. 1B).  
TRIM20Δ413 crystallized in space group P21 with 3 dimers in the asymmetric unit 
(Table S1 and Fig. S2A). The protein has an elongated structure formed by the 
CHS dimer (E414-N586) that is connected to the globular B30.2 domains (E589-
G776) through a short hinge region (Fig. 2A).  
The monomeric CHS domain folds into 4 helices (α1-α4). The first α-helix that 
harbors the predicted CC motif consists of 106 residues (E414-E520) and spans a 
length of approximately 155 Å (Fig. 2A). The designated L2 linker consists of two 
short helices α2 and α3 (E524-T539) followed by an 11 amino acid extended 
stretch and helix α4 (N551-Q586). A short linker of 2 amino acids (V587 and P588) 
connects the C-terminus of α4 to the B30.2 domain. The extended stretch and α4 
are oriented antiparallel to the helix α1 whereas helix α2 and α3 are in the 
peripheral turn forming a hairpin.  
The two protomers arrange in an antiparallel fashion along helix α1 with a shared 
interface of over 4700 Å2 that is created by all four helices including the extended 
stretch. As a result, the adjacent domains are distinctly placed where the N-termini 
of both monomers and consequently also the B-Box domains are positioned 167 
Å apart from each other, while the B30.2 domains are in proximity close to the 
central 2-fold axis of the dimer. 
The predicted two CC regions localize on the N- and C-terminal part of helix α1 
that due to the antiparallel dimerization structurally align and form a 2-helical coiled 
coil (2-CC; Fig. 2B). In case of TRIM20, residues L427 and L430 coil with residues 
L513’ and L516’ (the prime indicates residues from the other protomer). 
Additionally, an antiparallel 3-helical coiled coil is formed between residues in α1, 
α4, and α1’ (L484, V487, and V491; L560, and I557, I553; L458’, T455’ and F451’, 
Fig. 2B). Whereas the residues involved in the 2-CC are highly conserved in TRIM 
proteins, the 3-CC seems to be TRIM20 specific as these residues show no 
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sequence conservation (Fig. S1). Nevertheless, compared to the length of helix α-
1 and the size of the entire CHS domain, the CC character of the fold, i.e. the 
supercoiling of the helices, is small. In addition, the predicted CC motif and the 
designated L2 linker form one helical domain that is centrally located in TRIM 
proteins and provides the molecular scaffold for the placement of the adjacent 
domains (Fig. 2A and C). Therefore, we suggest the term CHS domain.  
In the central core around the 2-fold axis, helices α1 and α4 of both subunits form 
an antiparallel four helix bundle. This bundle is slightly bent, which leads to a 
curvature of the entire CHS domain, reminiscent of a coat hanger. Due to the 
crystal packing, the overall curvature found in the three dimers of the asymmetric 
unit varies (Fig. S2B). The changes in the curvature appear in the bundle while the 
rest remains identical suggesting the bundle of the CHS domain to be a flexible 
structural element.  
The B30.2 domain is only connected through a short linker point upwards along 
the 2-fold axis of the dimer, just like the hook on a coat hanger. As a consequence 
the CHS and the B30.2 domains do not share any interaction surface within the 
dimer structure. There is some degree of flexibility in the linker since the B30.2 
domain orientation relative to the CHS domain is different in the six monomers in 
the crystal (Fig. S2C). This flexibility is more pronounced in solution and 
demonstrated by the SAXS measurements (see below). 
An interesting feature of the X-ray structure is the contact between two neighboring 
dimers in the crystal that form a tetramer. This contact is created by the B30.2 
domains of one dimer (orange and purple), which interact with the extended stretch 
between α3 and α4 of the CHS domain of the other dimer (blue and green 
respectively) (Fig. 3A). An additional tetramer interface exists between the N-
terminal helices of the involved B30.2 domains (Fig. 3A). In total, the interaction 
surface amounts on average to 1830 Å2 which represents an unusually large 
crystal contact and can be interpreted to be a surface area of biological relevance 
(Fig. 3B). In support of this notion are in-vivo co-immunoprecipitation experiments 
by Papin et al. (15) which have shown that the isolated B30.2 domain interacts with 
an isolated B-Box-CHS construct. Further evidence comes from a construct 
TRIM20Δ303 (see also below) for which we see the formation of a tetramer in 
solution as indicated by size exclusion chromatography (Fig. S6D). 
We prepared a CHS-B30.2 domain construct for the homologue TRIM5α and 
performed SAXS measurements of two oligomeric species separated by SEC. 
These experiments reveal the presence of a dimer and a tetramer (Fig. S3A). The 
experimental radius of gyration (RG) of 4.5 and 5.3 nm for the dimer and the 
tetramer, respectively, match closely the calculated values using the TRIM20Δ413 
crystal structure (4.3 nm and 5.4 nm for the dimer and tetramer, respectively). The 
same is true for the determined maximal diameter (Fig. S3B-D).  
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Solution structure of TRIM20Δ413. SAXS measurements of the TRIM20Δ413 
reveal an increasing radius of gyration (RG) in a concentration dependent manner 
(Fig. S4A and B, Table S2) indicative for the presence of HO's in solution, with the 
tetramer being a likely intermediate. The RG for an infinitely diluted sample is 
4.27 nm, which is in perfect agreement with the calculated RG for the structure of 
the dimer (4.29 nm; Fig. S4C). The crystal structure however does not fit well to 
the experimental data (χ2=3.62) in the middle resolution scattering range s 
(nm-1)=0.8-1.8 (Fig. 4A and B). Since the Kratky plot reveals an interdomain 
flexibility (Fig. S4D), we generated a rigid body model by introducing flexibility 
between the CHS and the B30.2 domains, which significantly improves the fit to 
the experimentally determined scattering profile (χ2=2.01). In this derived model, 
one of the two B30.2 domains is arranged as in the crystal structure whereas the 
second B30.2 domain is rotated perpendicular to the dimeric 2-fold axis placing it 
sideways the CHS domain (Fig. 4A and C; Fig. S4F). A flexibility of the CHS 
domain, as it is suggested by the differences in curvature of the three dimers in the 
crystal structure, was not modeled. Nevertheless, conformational flexibility of the 
CHS domain is also suggested from SAXS data as the average diameter found in 
solution is around 160 Å, which is a little less than in the crystal structure (173 Å). 
Binding to pro-IL-1β. To elucidate the TRIM20Δ413 functionality, we investigated 
the reported binding to pro-IL-1β (15). Co-immunoprecipitation experiments 
revealed a direct interaction in-vitro between the purified proteins. The interaction 
required the presence of both the CHS and B30.2 domain as the individual 
domains could not be precipitated with pro-IL-1β (Fig. 5A). Surface Plasmon 
Resonance (SPR) experiments between TRIM20Δ413 and pro-IL-1β revealed a 
heterogeneous ligand behavior of TRIM20, suggesting that it is present in two 
states with measured affinities of 0.70 μM and 13.7 μM (Table S3 and Fig. S5A). 
A complex formation of the TRIM20Δ413 and pro-IL-1β in solution was detected 
by size exclusion chromatography (SEC). Stable complex formation however was 
only observed after incubating the proteins at room temperature (rt) whereas no 
complex was observed after incubation at 4 °C (Fig. 5B and Fig. S5B). The 
complex shows a large peak shift towards lower retention volumes corresponding 
to a molecular weight of approximately 400 kDa. This suggests a complex of more 
than one TRIM20Δ413 dimer (85.5 kDa) binding two pro-IL-1β (31.9 kDa) 
molecules but rather a higher oligomeric species. The complex is in equilibrium 
with its individual components which can be shown by reinjecting the isolated 
complex (Fig.S4C). Incubation of TRIM20Δ413 or pro-IL-1β alone does not show 
signs of higher oligomerization upon incubation at room temperature (Fig. 5C). The 
formation of an apparent higher oligomeric complex in solution could explain the 
heterogeneous ligand behavior of TRIM20 in the SPR experiments, where 
presumably the dimer binds with a low affinity, and oligomers of the dimer (e.g. 
tetramer) have a significantly increased affinity to pro-IL-1β. 
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Stereotype TRIM model. Between the N-terminal PYD domain and the CHS 
domain, TRIM20 has a 318 amino acid region of mostly unknown structure, which 
makes a prediction of the TRIM20 full length structure impossible. However, the 
TRIM20Δ413 structure reveals around 75% of a TRIM full length molecule missing 
only the N-terminal RING and B-Box domains (Fig. 1A). A linkage between the B-
Box and the CHS domain can be observed in the NMR structure of the TRIM29 B-
Box domain as its C-terminal eight residues form an α-helix that aligns with α1 
residues of the TRIM20 CHS domain (Fig. S6A) (29). As B-Box and RING domains 
share a common fold (30), a template for the connectivity between RING and B-
Box domain is given by TRIM18 tandem B-Box (B-Box1/2) structure. It features an 
interaction surface between the two adjacent B-Box domains and based on the 
hypothesis that there is an equivalent RING/B-Box interface, this TRIM18 B-Box1/2 
structure was used to generate a RING/B-Box model that was annealed to the CHS 
domain structure via the proposed domain linkage of TRIM29 (Fig. 6A and Fig. 
S6B). This model has a calculated RG and diameter of 6.2 nm and 21.1 nm, 
respectively. We prepared a corresponding TRIM20 construct starting just N-
terminal of the degenerated RING domain called TRIM20Δ303 which in SAXS 
provided a RG and diameter of 6.2 nm and 20.7 nm, respectively (Fig. S6D-I). This 
matches the values obtained for the presented model. 
Discussion 
TRIM proteins share a common domain architecture, of which structures of isolated 
domains have been determined. Due to the lack of structural information on the 
relative spatial arrangement of the domains in a full length TRIM context, detailed 
molecular mechanisms for ligand binding, self-assembly and signal transduction 
remained elusive. 
Here, the first high resolution structure of a TRIM CHS-B30.2 fragment at 2.4 Å 
resolution is presented. The predicted CC of the tripartite motif and the designated 
L2 linker to the B30.2 domain form one domain that we termed CHS domain. The 
elongated and helical CHS domain dimerizes over a large interface in an 
antiparallel fashion creating a coat hanger like structure and reveals the overall 
architecture of TRIM proteins. Furthermore, a crystal contact between two dimers 
provides a structural template for a B30.2 domain dependent formation of HOs. 
The necessity for dimerization for correct function has been shown for several 
TRIM proteins. In TRIM20, a deletion of the CHS domain leads to a monomeric 
and inactive protein (6). The same is true for the TRIM20 homologue TRIM5α, for 
which extensive mutational studies of the CHS domain have revealed insights into 
the precise contribution of this domain to the protein’s function. The fact that the 
CHS domain of TRIM20 can be functionally exchanged with the corresponding 
region of TRIM5α suggests a structural conservation and allows comparison (6). 
Rhesus TRIM5α that potently restricts HIV-1 by binding to the capsid surface of 
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the virion core, self-assembles into HOs (31). This oligomerization is dependent on 
the RING, B-Box as well as the CHS domain. Whereas dimerization is mediated 
by the CHS domain, the B-Box is thought to connect two dimers through a B-Box/B-
Box interaction (4). However, several residues in the CHS domain of TRIM5α have 
been identified that are crucial for HO association and retroviral restriction activity 
regardless of dimerization (21, 27, 32). Based on these findings a CHS/CHS 
interaction was proposed to contribute to the self-assembly.  
The CHS-B30.2 structure of TRIM20 provides a model to understand the structure 
function behavior of the CHS domain in TRIM proteins. The CHS domain not only 
acts as a scaffold for the surrounding domains but also as a mediator for 
dimerization and tetramerization.  
As the B-Box directly precedes the α1 helix of the CHS domain without an 
appreciable linker, the peripheral edge of the CHS domain is a critical factor for the 
correct orientation of the B-Box, which is formed by the N-terminus of the α1 helix, 
the C-terminus of the α1’ helix and by helices α2 and α3. Sequence comparison 
between several TRIM proteins shows that residues of these structural elements 
are conserved and mutations in the α2 helix of TRIM5α have been shown to 
interfere with the ability of the protein to self-assemble (Fig. S1; (32)). The TRIM20 
structure suggests that this effect is due to alterations in the relative positioning of 
the B-Box relative to the CHS domain. From the modeled stereotype TRIM protein, 
even a direct interaction between the α2 helix and the B-Box domain can be 
imagined (Fig. 6A).  
The 3-dimensional shape of a TRIM self-assembly has been shown by Ganser-
Pornillos and colleagues (28). They have revealed that a TRIM21-TRIM5α chimera 
spontaneously forms hexagonal lattices with a length between 180 and 205 Å of 
each hexagonal side (Fig. 6B). Together with the modeled RING finger and B-Box 
domain the elongated CHS fold is roughly 210 Å in diameter. This reveals that the 
elongated fold of the CHS is providing the dimensions for a putative TRIM lattice 
and one could assume a single dimer to be sufficient to match the length of the 
hexagonal lattice. However, this leads to only 3 B-Box domains at each hexagon 
edge due to the antiparallel dimer arrangement. As the B-Box connects two dimers 
via a complementary surface, it introduces a two-fold symmetry (4). Therefore 
having only three B-Box domains connecting three dimers imposes a symmetry 
problem. Based on the suggested CHS/CHS interaction, Ganser-Pornillos and 
colleagues have proposed that each side of the hexagonal lattice is made of a 
tetramer, placing six B-Box domains at each hexagon edge (Fig. 6C). The structure 
determined here also implies the formation of tetramers, however with a different 
arrangement of its domains. Instead of the proposed CHS/CHS interaction that 
connects two neighboring dimers, the tetramer is formed by the CHS/B30.2 
interaction (Fig. 3B and Fig. 6D). This suggests a new mechanism for TRIM lattice 
formation where all symmetry axis’ arising from oligomerization are parallel to each 
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other and perpendicular to the created surface. As a consequence, all B30.2 
domains are presented to the same side of the lattice, an essential feature missing 
in the previously suggested model. Our model is further supported by the ability of 
TRIM5αΔ132 to form tetramers and the fact that TRIM21-TRIM5α lattice formation 
was less efficient and less ordered, when the B30.2 domain was deleted (28). 
However, the general ability to form a lattice was retained. Remarkably, mutations 
of residues in TRIM5α that align with the extended stretch of the CHS domain 
cause a loss of restriction capability (27). Those TRIM5α mutants were stable 
dimers, but unable to form cytoplasmic bodies. As this stretch is distant from the 
outer conserved edge, one can assume that such mutations do not interfere with 
correct arrangement and connectivity to the B-Box and but rather lead to the 
inability to bind to the B30.2 domain of another dimer.  
Our data on the TRIM20Δ413/pro-IL-1β interaction also supports the physiological 
relevance of higher oligomers in case of TRIM20 as the complex formed between 
the two proteins indicates an oligomerization of TRIM20Δ413 dimers. The 
existence of a TRIM20 tetramer is suggested by the longer TRIM20Δ303 SEC 
profile. Additionally, SPR experiments suggest two states for TRIM20 with different 
affinities to pro-IL-1β that could be explained by a dimer binding with low affinity 
(13.7 μM) and a higher oligomer binding more affine (0.7 μM). The binding of pro-
IL-1β to TRIM20 is thought to inhibit the caspase-1 dependent maturation of the 
cytokine. This inhibition might be disrupted in case of FMF mutations (15). 
Interestingly, several FMF associated residues are located within the tetramer 
interface, these include I591, A595, L649 and R653 (33). Mutations could alter the 
affinity of dimers to assemble into tetramers, therefore preventing TRIM20 to 
effectively bind pro-IL-1β and inhibit its maturation. Mutational studies have to 
address the particular role of TRIM20 HO’s and the involved tetramer interface in 
the binding to pro-IL-1β and the putative inhibition of is maturation.  
As the designated L2 linker is fully structured and forms together with the CC motif 
the CHS domain, the flexible connection to the B30.2 domain is only mediated by 
a short hinge region that allows the B30.2 domain to adopt different orientations 
relative to the CHS domain. Together with the flexibility of the CHS domain, this 
feature adds to the structural and functional flexibility of TRIM proteins. For 
instance, various antibody coated surfaces, such as bacteria, non-coated viruses 
or latex beads are recognized by the intracellular Fc-receptor TRIM21 and induce 
downstream signaling (34). TRIM5α can adapt to different capsid curvatures and 
restricts various retroviruses. The presented structure reveals how TRIM proteins 
can adopt their modular structure to adapt to differently presented ligands.  
When comparing different TRIM proteins in sequence N-terminal of the B30.2 
domain, namely the extended stretch and helix α4, it is noteworthy that 
conservation in length and sequence identity is low (Fig. S1). For instance, TRIM27 
has a similar length of the α4 helix as TRIM20, while TRIM5α, 21 and 22 are shorter 
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in sequence. This suggests that helix α4 and the extended stretch act as a ruler to 
specifically define the position the B30.2 domains, accommodating for ligand 
specificity of TRIM proteins.  
Overall, the TRIM20Δ413 reveals the antiparallel dimerized and elongated 
structure of the CHS domain leading to distinct positioning of the adjacent domains, 
which are in case of the B30.2 domain flexibly connected. The structure fits very 
well to the functional data on TRIM5α with respect to the overall architecture and 
the domain contributions for lattice formation. The ability of TRIM5α to form 
tetramers strengthens the hypothesis, that the presented TRIM20 tetramer 
structure resembles a building block for lattice formation. The quantitative results 
of the interaction between TRIM20 and pro-IL-1β set the basis for the analysis of 
FMF associated mutations and their effect towards pro-IL-1β binding and putative 
inhibition of the cytokine’s activation.  
Experimental Procedure 
Cloning, expression and purification, SAXS experiments, Co-IP experiment, 
surface Plasmon resonance analysis, size exclusion experiments and model 
building are described in the SI Methods. 
Crystallisation and structure determination 
First crystals were found in 0.1 M Tris-AcOH, pH 8-8.5, 0.2-0.4% (w/v) Cystamine, 
0.2 M LiSO4, 8% (w/v) PEG 20’000, 8% (w/v) PEG 550 MME using sitting drop 
vapor diffusion at 20 °C. TRIM20Δ413 (7.5 mg/ml) was mixed in a 1:1 ratio with 
mother liquor. The obtained crystals were used for micro-seeding in 0.1 M Tris-
AcOH, pH 7.4-8.0, 0.26% (w/v) Cystamine, 0.2 M LiSO4, 8% (w/v) PEG 20’000, 
8% (w/v) PEG 550 MME using sitting drop vapor diffusion at 20 °C. The protein 
sample was concentrated to 5 mg/ml and mixed in a 1:1 ratio. Crystals grew within 
24 h and were fished within 18 days. Prior to flash freezing in liquid nitrogen, 
crystals were soaked in the mother liquor supplemented with 20% (v/v) ethylene 
glycol. A native data set of a TRIM20Δ413 crystal was recorded at the X06SA beam 
line of the Swiss Light Source (Paul-Scherrer Institut, Villigen, Switzerland). The 
protein crystallized in P21 with 6 molecules in the asymmetric unit forming 3 dimers. 
Data was indexed, integrated and scaled with XDS(35) to a resolution of 2.4 Å. 
Molecular replacement was done with Phaser (36) using the B30.2 domain of 
TRIM20 as search model (pdb entry: 2WL1). Model building and manual fitting was 
done in Coot (37). Refinement was performed with Phenix (38). In the final model, 
98% of all residues are in the favored ramachandran area and no outliers. The 
accession code is 4cg4. 
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Figure legends 
Figure 1 
Central position of the CHS domain in TRIM proteins and its importance in 
dimerization. (A) Schematic representation of the domains of TRIM proteins 
comprising a RING, B-Box, and CHS domain. In the literature the CHS domain is 
referred to as coiled coiled domain with a L2 linker that connects to the C-terminal 
B30.2 domain. TRIM20 is a RING-less TRIM member and has a long N-terminal 
insertion composed of a PYD domain and a long linker region. For crystallization a 
construct starting at position 414 was designed. (B) Sedimentation velocity 
analytical ultracentrifugation of the B30.2 domain and the CHS-B30.2 fragment of 
TRIM20 show a monomer and a dimer, respectively. The calculated monomeric 
masses are 23.305 kDa and 42.737 kDa for the B30.2 domain and the 
TRIM20Δ413 construct, respectively. 
Figure 2 
Crystal structure of TRIM20Δ413. The crystal structure of one of the three dimers 
(chain A and B) in the asymmetric unit is presented. The chains of monomer A and 
B are colored in blue and red, respectively. The helices of each CHS monomer are 
numbered α-1 to α-4. The parts of the CHS domain that show a 2 helical (2-CC) or 
3 helical coiled coil (3-CC) are indicated and depicted in more detail in B. (A) The 
dimer is shown from a side and a top view and its dimensions indicated. (B) 
Residues involved in the 2-CC (top) and 3-CC (bottom) are shown as sticks and 
labeled in the corresponding color of the helix. (C) Topology of the CHS domain 
including its structural motifs are shown schematically.  
Figure 3 
Tetramer interface. (A) The crystal contact between two dimers is shown in a 
cartoon representation. Chain A and B are colored as in Fig. 2. The second dimer 
made of chain C and D is colored in orange and green, respectively. The black box 
indicates the display detail shown in B. (B) Detailed view of half of the tetramer 
interface. Residues involved in the interface are depicted in sticks and hydrogen 
bonds are indicated by black dashed lines. The coordinated water between the 
B30.2 domains is shows as a red sphere. 
Figure 4 
Solution structure of TRIM20Δ413. (A) Data extrapolated to infinite dilution is 
shown together with the fits of the crystal structure and rigid body modeling with 
the indicated χ2 values. (B) The crystal structure is shown in a cartoon 
representation next to the (C) rigid body model. The orientation found to be similar 
to the crystal structure is shown in a blue surface representation. The other 
orientation of the B30.2 domain found in the rigid body fit is colored violet. 
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Figure 5 
Interaction between TRIM20 and pro-IL-1β. (A) 10 μM of the indicated TRIM20 
constructs were incubated with 10 μg FLAG-tagged pro-IL-1β in 100 µl total 
volume. Complex was co-immunoprecipitated using ANTI-FLAG® M2 Affinity Gel 
(Sigma-Aldrich) and subjected to SDS-PAGE analysis. (B) TRIM20Δ413, pro-IL-
1β and a mixture of both proteins (complex) were incubated at room temperature 
and their SEC elution profiles are shown with the corresponding retention volumes 
of 1.27 ml, 1.64 ml, and 1.81 ml for the complex, TRIM20Δ413 and pro-IL-1β, 
respectively. Co-elution of both proteins in the appearing complex peak was 
verified by SDS-PAGE of the fractions indicated by black horizontal bars. Number 
1 and 2 indicate the bands corresponding to TRIM20Δ413 and pro-IL-1β, 
respectively. The asterisks indicate TRIM20 multimers.  
Figure 6 
Models of TRIM full length and lattice formation. (A) The modeled TRIM full length 
structure is shown in a cartoon representation with the B30.2 domain, CHS, B-
Box2, and RING domain colored in orange, red, green, and blue, respectively. The 
coordinated Zn2+ atoms are shown in grey spheres. (B) Schematic drawing 
showing the dimensions of the reported hexagonal lattice formed by a 
TRIM21/TRIM5α chimera (28). Part of the lattice that is shown in detail in C and D 
is indicated in red with the central 3-fold axis depicted by the black triangle. (C) The 
currently proposed model suggests parallel arranged TRIM dimers that form 
tetramers via a L2/L2 contact. The tetramers assemble via B-Box/B-Box 
interactions into the hexagonal lattice. (D) Lattice formation using the B30.2 
dependent tetramer as observed in the TRIM20 crystal. The revealed flexibility of 
the B30.2 domains is indicated by the arrows. 
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Figures 
Figure 1 
 
 
Figure 2 
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Figure 3 
 
 
Figure 4 
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Figure 5 
 
 
Figure 6 
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4.2 Supporting Information 
SI Methods 
Construction of Expression Plasmids 
The multiple cloning site 1 (MCS1) of the transfer vector pFBDM (1) was modified 
to enable fragment exchange (FX) cloning (2). The SapI restriction site between 
the transposon element Tn7R and the Col-E1 origin of replication was removed 
using Quikchange mutagenesis (Invitrogen). An NdeI restriction site was inserted 
into the MCS1 by Quikchange. The FX-cassette of the pBXC3H vector (2) was 
used as template (incl. coding region for C-terminal His10-tag and 3C cleavage site) 
and cloned into the modified pFBDM vector using NdeI and XbaI restriction sites 
yielding a pFX3CH vector. The NdeI restriction site was later removed. All TRIM20 
constructs and human TRIM5αΔ132 were cloned into the pFX3CH template vector. 
Primers and coding regions are stated in Table S4.  
A similar procedure as for pFX3CH was applied to modify a pET28 (Novagen) 
vector. The SapI site near the BR322 origin of replication was removed with 
Quikchange. The FX-cassette of pBXH3C (incl. coding region for N-terminal His10-
tag and 3C-cleavage site) was inserted using the NdeI and XhoI restriction yielding 
a pET28-FXH3C vector. Pro-IL-1β (codon optimized for E.coli expression) was 
cloned into the pET28-FXH3C vector using primers as stated in Table S4.  
Expression and Purification 
All TRIM constructs were expressed in Sf9 cells using the manufactures protocol 
(Invitrogen). Cells were harvested after 48-72 h expression at 27 °C. Sf9 cells 
expressing TRIM20Δ413 were lysed in lysis buffer (50 mM Tris-HCl, pH 8, 300 mM 
NaCl, 20 mM imidazole, DNAse I, RNase I, Benzoase, and EDTA-free complete 
inhibitor cocktail (Roche Diagnostics)) using an Emulsi-Flex C3 homogenizer 
(Avestin, Canada). Cell debris was centrifuged (1 h, 4 °C, 20’000 rpm) and 
supernatant applied to Protino Ni-NTA agarose (Machery Nagel). His-tag was 
cleaved by His-3C Protease, the sample dialysed in 50 mM Tris-HCl, pH 8, 150 mM 
NaCl, 10 mM imidazole, 0.5 mM TCEP, and reapplied to Ni-NTA agarose. Cleaved 
TRIM20Δ413 was dialyzed in low salt buffer (20 mM Tris-HCl, pH 8, 50 mM NaCl, 
0.5 mM TCEP) and applied on a RESOURCE Q anion exchange column (GE 
Healthcare). The protein was eluted with 7.5% high salt buffer (20 mM Tris-HCl, 
pH 8, 1 M NaCl, 0.5 mM TCEP) and dialysed in 20 mM Tris-HCl, pH 8, 100 mM 
NaCl, 0.5 mM TCEP. The protein could be stored at 4 °C for up to two weeks, or it 
was frozen in liquid nitrogen and stored at -80 °C until further use.  
Human TRIM5Δ132 was purified as described above and after His-tag removal 
applied on a Superdex 200 (10/300 GL; GE Healthcare; 50 mM Tris-HCl, pH 8, 
100 mM NaCl, 0.5 mM TCEP). Fractions containing dimeric human TRIM5Δ132 
were pooled and stored at 4°C until further use. 
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All other TRIM constructs were lysed using 0.5% CHAPS in lysis buffer, and 
purified as described above. After His-tag removal the proteins were applied on a 
Superdex 200 (10/300 GL; GE Healthcare; 50 mM Tris-HCl, pH 8, 150 mM NaCl, 
0.5 mM TCEP). Proteins were stored at 4°C or frozen in liquid nitrogen after 
addition of glycerol to a final concentration of 8.7% (v/v). For TRIM20-CHS 300 
mM NaCl was used throughout the purification. For TRIM20Δ303 400 mM NaCl 
was used in the elution buffer and for SEC chromatography to separate 
TRIM20Δ303 from aggregates. Fractions corresponding to dimeric TRIM20Δ303 
were pooled and analyzed in a second SEC in 50 mM Tris-HCl, pH 8, 150 mM 
NaCl, and 0.5 mM TCEP. 
 Pro-IL-1β was expressed in E.coli BL21 (DE3) strain. Cells were grown in LB-
media at 30 °C to an OD600nm of 0.8, cooled down at 4°C for 30 min and expression 
induced with 0.1 mM IPTG (OD600nm of 1.0). After 15 h expression at 18 °C, cells 
were harvested (4°C, 20 min, 4000 rpm) and lysed in 50 mM Tris-HCl, pH 8, 150 
mM NaCl, 10 mM imidazole, DNAse I, RNase I, lysozyme, 0.5 mM PMSF, EDTA-
free complete inhibitor cocktail (Roche Diagnostics) using an Emulsi-Flex C3 
homogenizer (Avestin, Canada). Lysate was cleared and supernatant applied to 
Ni-NTA agarose. His-tag was cleaved by His-3C Protease, the sample dialysed in 
50 mM Tris-HCl, pH 8, 50 mM NaCl, 0.25 mM TCEP) and reapplied to Ni-NTA 
agarose. As a final purification step the sample was applied on a Superdex 200 in 
50 mM Tris-HCl, pH 8, 50 mM NaCl, 0.5 mM TCEP). Fractions corresponding to 
monomeric pro-IL-1β were pooled and either used directly or frozen in liquid 
nitrogen after the addition of 8.7% glycerol and stored at -80 °C. 
Co-IP experiments 
10 μg of FLAG-pro-IL-1β were incubated with 10 μM TRIM20Δ412, TRIM20-B30.2 
or TRIM20-CHS in a total volume of 100 μl (50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 
0.05% Tween 20). The mixture was incubated for 30 min at room temperature (RT) 
to allow complex formation. Putative complexes were co-immunoprecipitated using 
20 μl ANTI-FLAG® M2 Affinity Gel (Sigma-Aldrich) for 10 min at RT. Beads were 
washed 3 times, and proteins eluted with 45 μl 2x SDS loading buffer. Eluted 
samples were analyzed by SDS-PAGE and visualized using silver staining (3). 
Surface Plasmon Resonance 
The interaction between TRIM20Δ412 and pro-IL-1β was measured on a 
ProteOnTM XPR 36 using a ProteOnTM GCL sensor chip (Bio Rad) equilibrated with 
running buffer (PBS, pH 7.5, 0.02% Tween 20). Monoclonal Anti-c-Myc IgG1 (20 
μg/ml in 10 mM acetate, pH 5; Roche Diagnostics) was immobilized using amine 
coupling chemistry until the chip was saturated (6000-6400 RU). TRIM20Δ412 (1 
μM) was applied to the immobilized antibody in running buffer and equilibrated until 
a stable baseline was reached (550-600 RU TRIM20Δ412; ΔRU < 0.2 RU/min). In 
total 5 lanes were immobilized with TRIM20Δ412. The sixth lane was coated with 
antibody only and used as a reference for unspecific binding. Single shot kinetic 
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was applied using a two-fold dilution series of pro-IL-1β in running buffer (1.56, 
3.125, 6.25, 12.5, 25 μM). For each lane two single shot experiments were 
performed. Data was double referenced against buffer and the antibody control 
lane. Binding affinity (KD) was determined kinetically for each experiment using the 
heterogenous ligand model implemented in the ProteOnTM-Software (Bio Rad). 
The mean and standard deviation of the measured KDs was determined using 
GraphPad Prism6 (GraphPad Software). 
Size exclusion chromatography analysis of complex formation 
TRIM20Δ413 was mixed with freshly prepared pro-IL-1β. 3 mg of each protein were 
mixed and concentrated to a final concentration of 19 mg/ml. The buffer was 
exchanged to 20 mM Tris-HCl, pH 8, 100 mM NaCl, 0.5 mM TCEP while 
concentrating. Individual proteins were concentrated to 8 mg/ml and buffer was 
exchanged as for the complex. Samples were incubated for 60 min at room 
temperature or 20 h at 4 °C, centrifuged (14’000 g, 10 min, 4 °C) and 5 μl injected 
onto a Superdex 200 (5/150 GL, GE Healthcare) in 20 mM Tris-HCl, pH 8, 100 mM 
NaCl, 0.5 mM TCEP at 4 °C. 50 μl fractions were collected, analyzed by SDS-
PAGE and visualized using silver staining.  
Small-angle X-ray scattering 
SAXS data were collected at the Petra III (P62) beam line at the Deutsches 
Elektronen Synchroton (DESY), Hamburg. The incident wavelength was 1.24 Å. 
Data was recorded on a 2M Pilatus detector for the angular range of s between 
0.0668-4.336 nm-1 (s=4π sin (θ)/λ, where 2*θ is the diffraction angle and λ the 
wavelength of the incident beam). All samples were measured at 10 °C. 
TRIM20Δ413 was measured in PBS and 5 mM DTT at several concentrations (1.7, 
2.88, 4.6, 8.75, 13.3 mg/ml). TRIM20Δ303 was measured at several concentration 
(0.87, 6.1, 8.7 mg/ml) in 20 mM Tris-HCl, pH 8, 400 mM NaCl, 1 mM TCEP. 
TRIM5Δ132 was concentrated to 10 mg/ml and injected onto a Superdex 200 
(10/300 GL; GE Healthcare; 50 mM Tris-HCl, pH 8, 100 mM NaCl, 0.5 mM TCEP) 
prior to SAXS data collection. Peak fractions were measured by SAXS immediately 
after elution from size exclusion. Data was processed with PRIMUS (4) and a 
scattering curve extrapolated to infinite dilution was created using ALMERGE (5). 
The pair distribution function (P (r)) was calculated with GNOM (6). Radius of 
gyration RG was estimated from the Guinier plot using PRIMUS and the P (r) 
function using GNOM. Rigid body modeling was carried out in CORAL(7) defining 
residues 586-590 of TRIMas a flexible linker. Comparison with the crystal structure 
and the experimental scattering profile was done with CRYSOL(8). The P(r) 
function of the X-ray structure and the rigid body fit was generated using SOMO (9). 
Sequence alignment 
Sequences used correspond to the UniProt entries O15553, Q9C035, P19474, 
Q8IYM9, P14373 for TRIM20, TRIM5α, TRIM21, TRIM22, TRIM27, respectively. 
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Alignments were generated using T-coffee (10) and Jalview (11). Coiled coil 
predictions are taken from secondary structure predictions using Jpred 3 (12). 
Modeling 
The TRIM full-length model was generated using the MODELLER software 
(version 9.12) (13). Homology modeling was performed according to the Advanced 
Tutorial on the MODELLER homepage 
(http://salilab.org/modeller/tutorial/advanced.html) with a few modifications. The 
templates for the modeled RING and for the modeled B-Box were aligned 
separately using the SALIGN function and were subsequently merged manually to 
yield one multiple structure alignment for all the templates. TRIM5 RING (pdb entry 
2ECV, residues 8-69 (14)) and B-Box1 of the TRIM18 tandem B-Boxes (pdb entry 
2JUN, residues 114-173 (15)) served as templates for the modeled RING. TRIM5 
B-Box (pdb entry 2YRG, residues 8-51 (16)), TRIM29 B-Box (pdb entry 2CSV, 
residues 16-63) and B-Box2 of the TRIM18 tandem B-Boxes (pdb entry 2JUN, 
residues 171-214) were taken as templates for the modeled B-Box. The target 
sequence, corresponding to residues 1-131 of human TRIM5α followed by 
residues 413-419 of TRIM20, was aligned to the pre-aligned template structures 
using the SALIGN function. To incorporate the zinc atoms into the modeling 
process, following lines were added to the alignment and modeling scripts: 
Env.io.atom_files_directory = [‘.’, ‘../atom_files’] and env.io.hetatm = True. The final 
multiple sequence alignment of template structures and target sequence is shown 
in Supplementary Fig. 4. A tandem model of RING and BBox domains was built 
using the automodel class of MODELLER and structurally aligned onto the 
TRIM20Δ413 structure via the shared pyrin residues 413-419 yielding the TRIM 
full-length model. 
Analytical ultracentrifugation 
The B30.2 domain, expressed and purified as described (17), and TRIM20Δ413 
were measured in PBS (pH 7.4) 10 mM β-Mercaptoethanol at a concentration of 
0.6 mg/ml and 0.8 mg/ml, respectively. The sedimentation velocity measurements 
were carried out at 4°C on a ProteomeLab XL-1 (Beckman Coulter) ultracentrifuge 
at a speed of 30000 rpm. Data was analyzed with SEDFIT (18). 
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Supplementary Figure legends 
Figure S1 
Sequence alignment of the CHS domain of several TRIM20 homologues. Identical 
and similar residues are depicted by black and grey boxes, respectively. The 
predicted bipartite coiled coils for every TRIM are indicated by lines on top of the 
sequences and colored as indicated next to the protein names. The predicted L2 
linker is marked by the grey line. Secondary structure elements as seen in the 
TRIM20 structure are indicated below the sequences. Residues that form the 2 
helical coiled coil (2-CC) and 3 helical coil coiled (3-CC) are connected by black 
lines.   
Figure S2 
 Different dimers in the asymmetric unit. Three dimers are found in the asymmetric 
unit (chains A&B, C&D, and E&F). For visualization only dimer of chain A&B and 
C&D were used. Dimer of chain E&F is similar as dimer CD. (A) Superposition of 
the TRIM20 dimers are shown in a top and side view. The chains are colored in 
blue, red, orange and green for monomer A, B, C and D, respectively. (B) For a 
better visualization of the differences between the CHS monomers residues 486-
560 of each monomer were superposed using Superpose (19). For each monomer 
the corresponding second protomer is shown in transparent black. (C) The hinge 
region between the helix α4 and the B30.2 domain is visualized by superposing 
the first N-terminal helix of each B30.2 domain (residues 590-595, shown in black). 
Helix α4 of each monomer is colored as in A and B.  
Figure S3 
TRIM5Δ132 dimer-tetramer. (A) Size exclusion profile of TRIM5Δ132 reveals the 
presence of two oligomeric states. Fraction of the peak 1 that was reinjected unto 
SEC is indicated by the black bar. Its SEC profile is shown in the middle of the 
panel, showing an identical elution profile. SDS-PAGE analysis of all fractions of 
peak 1 and 2 are shown on the left indicating that both peaks origin from 
TRIM5Δ132. (B) Immediately after SEC peak 1 and 2 were analyzed by SAXS. 
The resulting scattering curves are plotted in log X-log Y manner. Their guinier plot 
is shown in the inlet and reveals linear behavior for both species. (C) Scattering 
profile of peak 1 & 2 are shown together with the calculated curves of the 
TRIM20Δ413 tetrameric and dimeric structure, respectively. (D) Biophysical values 
for TRIM5αΔ132 obtained by SEC and SAXS analysis are stated in comparison to 
the calculated values for TRIM20Δ413. Values were obtained using1) DARA (20), 
2) CRYSOL, 3) see Table S2, 4) based on amino acid sequence, 5) and via mass 
spectrometry analysis of the monomer. 
Figure S4 
SAXS data. (A) and (B) Overlay of experimental scattering curves are shown for 
all measured concentrations as indicated. For structural modeling a dataset was 
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created corresponding to an infinite dilution. In (A) and (B) the data is plotted as X-
log Y and log X-log Y, respectively, with the error bars depicted as lines in the 
corresponding color. (C) For the dataset extrapolated to infinite dilution (black dots) 
the guinier plot (black line) shows linearity without signs of interparticle attraction. 
(D) The Krakty-plot (black dots) shows a typical curve for a two domain protein with 
interdomain flexibility. The errors are depicted by grey lines. (E) The P(r) curve 
approaches zero for r = rmax. For r = 0, P(r) does not fully approach zero 
suggesting a minimal mismatch of the buffers in the sample and in the buffer 
control. (F) Overlay of the P(r) curve derived from the experimental data, the crystal 
structure and the rigid body fit is shown. 
Figure S5 
Binding of TRIM20 to pro-IL-1β. (A) Typical sensogram of the SPR measurements 
is shown. Myc-TRIM20Δ412 was immobilized and a dilution series of pro-IL-1β, as 
indicated, was subjected (black lines). The obtained fit for every concentration 
using the heterogeneous ligand model is shown by the grey lines and the resulting 
KDs and their standard deviations (s.d.) are stated. (B) SEC profile for pro-IL-1β, 
TRIM20Δ413 and a mixture of both proteins incubated for 20 h at 4 °C are shown 
in the corresponding color. The dotted lines indicate the retention volumes for the 
individual proteins and the complex as seen in Fig. 5B. (C) SEC profile of a mixture 
of both proteins (Complex) incubated at room temperature is shown (left y-axis). 
The fraction that was reinjected is indicated by the black bar and its SEC profile 
shown (Reinject complex; right y-axis).  
Figure S6 
Modeling a stereotype TRIM full length protein. (A) The periphery of the TRIM20 
CHS domain and the NMR structure of the TRIM29 B-Box (pdb code: 2CSV) are 
shown in a cartoon representation. A sequence alignment of the structural overlap 
between the two structures is shown in the middle. Residues of the B-Box are 
colored in green. Residues that overlap in both structures are colored solid black 
while the rest of the CHS domain is colored transparent red. (B) The structure of 
the TRIM18 B-Box1/2 tandem motif (pdb code: 2JUN (15)), the TRIM5α RING (pdb 
code: 2ECV (14)), and the TRIM5α B-Box2 (pdb code: 2YRG (16)) are shown in a 
cartoon representation. (C) Multiple sequence alignment of the template structures 
TRIM5 RING, TRIM5 B-Box, TRIM29 B-Box and TRIM18 tandem B-Boxes (pdb 
entries 2ECV, 2YRG, 2CSV and 2JUN, respectively) and the target sequence used 
for homology modeling. Numbering of residues correspond to the pdb entries 
including the zinc atoms (z). Residues of the RING, B-Box and CHS domains are 
framed in blue, green and red, respectively. (D) Schematic representation of the 
TRIM20Δ303 construct and a TRIM full length protein. SEC profile and SDS-PAGE 
of the purified TRIM20Δ303are depicted. The corresponding elution volumes on a 
S200 (10/300) are indicated. Scattering curves of TRIM20Δ303 and a merged 
curve are illustrated in a X-log Y (E) and log X-log Y (F) manner. The guinier plot 
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(G), Krakty plot (H), and the radial distribution (I) are shown for the merged 
scattering curve. (K) The biophysical properties of TRIM20Δ303 are listed in 
comparison to the calculated values of the presented full length TRIM model. 1) 
The experimental molecular weight (MW) of TRIM20Δ303 was calculated using the 
I(0) of TRIM20Δ413 as standart (see Table S2). 2) The calculated MW is based on 
the amino acid sequence. 3) Values were derived using CRYSOL.  
Supplementary Figures 
Figure S1 
 
 
Figure S2 
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Figure S3 
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Figure S4 
 
 
Figure S5 
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Figure S6 
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Supplementary Tables 
Table S1. X-ray data collection and refinement statistics 
 TRIM20Δ413 
Data collection  
Space group P21 
Cell dimensions  
 a, b, c (Å) 69.82 388.21 70.88 
 ()  90 116.52 90 
Resolution (Å) 48.53 - 2.4 (2.486 - 
2.4)* 
Rmerge 0.1724 (1.857)* 
I / I 9.77 (0.88)* 
Completeness (%) 98.96 (93.07)*  
Redundancy 7.4 (6.6)* 
CC1/2 99.6 (51.3)* 
  
Refinement  
Resolution (Å) 48.53 – 2.4 
No. reflections 129414 
Rwork / Rfree (%) 21.15 / 26.07 
No. atoms  
 Protein 17943 
 Ligand/ion 68 
 Water 33 
B-factors  
 Protein 54.8 
 Ligand/ion 67.7 
 Water 33.6 
R.m.s. deviations  
 Bond lengths (Å) 0.012 
 Bond angles () 1.37 
The dataset was recorded from a single crystal. 
 *Values in parentheses are for highest-resolution shell. 
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Table S2: SAXS data collection and processing  
 TRIM20Δ413 
Data collection  
Instrument Petra 12; Pilatus 2M  
Beam geometry  0.2x0.12 mm2 
Wavelength (Å) 1.24 
s range (nm-1) 0.0668-4.336 
Exposure time (s) 0.05 
Concentration range [mg/ml] 1.7-13.3 
Temperature 283 
  
Structural parameters  
I(0) (cm-1) [from P(r)] 9184 (± 8.47) 
Rg (nm) [from P(r)] 4.27 (± 0.056) 
I(0) (cm-1) (from guinier) 9100.84 (±20.24) 
Rg (nm) (from guinier) 4.15 (± 0.023) 
Dmax [nm] 15.9 
Porod volume estimate (Å3) 131.72 
Dry volume calculated from structure (Å3) 100.5 
 
Molecular mass determination 
Partial specific volume (cm3g-1) 
 
 
1.37 
Molecular mass Mr [kDa] 90.0 
Molecular mass Mr [kDa; analytical 
ultracentrifugation] 
78.4 
Monomeric Mr from MS analysis [kDa] 
 
42.737 
Software employed  
Primary data reduction 
Data processing 
Extrapolation to infinite dilution 
Ab initio analysis 
Validation and averaging 
Rigid-body modelling 
Multiple conformation modelling 
Computation of model intensities 
3D graphics representation R.m.s. deviations 
PRIMUS 
PRIMUS / GNOM 
ALMERGE 
DAMMIN 
DAMAVER 
SASREF 
EOM 
CRYSOL 
PyMOL 
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Table S3. Kinetic data of SPR experiment 
kon1 [1/Ms] koff 1 [1/s] KD1 [μM] Rmax1 [RU] 
4.17*102 
±1.4*102 
2.83*10-4 
±0.59*10-4 
0.70 ± 0.15 20.3 ± 3.88 
kon2 [1/Ms] koff 2 [1/s] KD2 [μM] Rmax2 [RU] 2 [RU] 
3.96*103 
±1.32*103 
5.10*10-2 
±1.38*10-2 
13.7 ± 4.4 25 ± 3.27 2.55 ±0.54 
 
Table S4. Construct design 
Construct 
Coding 
region 
Tag Forward primer Reverse primer 
Template 
vector 
TRIM20Δ413 414-781 - 
atatatgctcttctagtgaggtcgccctgg
aac 
tatatagctcttcttgcgtcaggcccctga
cc 
pFX3CH 
TRIM20Δ412 413-781 
N-terminal c-Myc 
(EQGKLISEEDL) 
atatatgctcttctagtgagcagaaactc
atctctgaagaggatctggaggaggttg
ccc 
tatatagctcttcttgcgtcaggcccctga
cc 
pFX3CH 
TRIM20-CHS 413-577 
N-terminal c-Myc 
(EQGKLISEEDL) 
atatatgctcttctagtgagcagaaactc
atctctgaagaggatctggaggaggttg
ccc 
tatatagctcttcatgcggtttctgagaag
tac 
pFX3CH 
TRIM20-
B30.2 
577-781 
C-terminal c-Myc 
(EQGKLISEEDL) 
atatatgctcttctagtctgcgttcagaaat
gg 
tatatagctcttcatgccagatcctcttca
gagatgagtttctgctcgtcaggcccctg
acc 
pFX3CH 
TRIM20Δ303 304-781 - 
atatatgctcttctagtggaaggccacca
gac 
tatatagctcttcttgcgtcaggcccctga
cc 
pFX3CH 
TRIM5αΔ132 133-493 - 
atatatgctcttctagtgattacaaagac
gatgacgataaagaggttgcccgg 
tatatagctcttcatgcagagcttggtga
gc 
pFX3CH 
Pro-IL-1β 
Full 
length 
C-terminal FLAG 
(DYKDDDDK) 
atatatgctcttctagtgcggaagtgccg
gaac 
tatatagctcttcatgccttatcgtcgtcat
ccttgaatcgctgctcacaaactgc 
pET28-
FXH3C 
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5 Final Discussion and Outlook 
The emphasis of this thesis was to elucidate three main subjects: i) The structural 
characterization of pyrin fragments with a focus on the C-terminal B30.2 domain, 
ii) effects of FMF associated mutations located in the putative binding epitope of 
the B30.2 domain, iii) and the biochemical analysis of ligand binding to pyrin. 
At the beginning of this thesis, no in-vitro information was available for pyrin. 
Establishing protocols for the expression and purification of pyrin fragments 
allowed us to structurally and functionally characterize the protein.  
The structure of a C-terminal fragment of pyrin revealed the antiparallel 
dimerization mediated by the central helical scaffold domain and the arrangement 
of the single domains. This information was used to construct a stereotype full 
length TRIM protein that provides yet unknown insights into the architecture of this 
important class of proteins. Additionally, the presented tetramer provides further 
information on the contribution of the single domains to the TRIM self-assembly. 
The work on the isolated B30.2 domain revealed the structural changes induced 
by FMF associated mutations in the putative binding epitope that show both local 
effects on the shape of the epitope and but also on the conformational flexibility of 
entire loops. This sheds light into specific characteristics of the binding epitope of 
the pyrin B30.2 domain. 
As the function of pyrin has exclusively been studied in-vivo, there is a lack of 
biochemical data on interaction of pyrin to putative ligands. We established 
protocols for the in-vitro characterization of the interaction to pro-IL-1β and suggest 
a tight binding between these proteins, when pyrin is present as a tetramer. 
In summary, the thesis sets the basis for further in-vitro characterization of the 
protein pyrin. There are 4 major questions to be answered. 1) Is pyrin inhibiting the 
maturation of pro-IL-1β in-vitro? 2) Is the binding of pyrin to pro-IL-1β solely 
mediated by the tetramer? 3) Do FMF associated mutations alter the 
thermodynamics of tetramerization or the binding affinity to pro-IL-1β? 4) What is 
the binding interface between pyrin and pro-IL-1β?  
These questions should further reveal the exact mechanism on how pyrin functions 
both in an anti- as well as pro-inflammatory manner, thereby elucidating the effects 
induced by FMF mutations.  
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